All reports.

Veriff

A profitable, fast-growing identity-verification leader whose quality is high but whose price is unconfirmed against a three-year-stale $1.5B mark.

Valuation

$1.5B

Revenue run-rate

$110M

ARR

$110M

Growth

83%

Noom

Noom is a real, large-scale consumer-health brand whose 2021 $3.7B mark is no longer credible — secondary markets already imply ~$720M — and whose investability now hinges on whether the GLP-1 Noom Med pivot can offset behavioral-app revenue decline and structural disruption.

Valuation

$3.7B

Revenue run-rate

$400M

Monolith Materials

A first-of-its-kind commercial plasma-pyrolysis producer with real technology and blue-chip backing, but thin public financials, single-plant scale, customer/loan concentration and a DOE loan under cancellation threat warrant deeper diligence before underwriting the $1B+ valuation.

Valuation

$1B

Incode Technologies

A fast-growing LATAM identity-verification leader with real scale and revenue, but a stretched reported valuation, concentration, and biometric regulatory exposure warrant close tracking before conviction.

Valuation

$1.3B

Revenue run-rate

$170M

ARR

$170M

Growth

80%

Avoca

Avoca has genuine vertical AI traction and elite investor validation in an underpenetrated home-services market, but the $1 billion valuation on undisclosed eight-figure ARR creates too wide an uncertainty band to underwrite without data-room access — warranting a track posture until key unit economics are verified.

Valuation

$1B

Divert

Divert has assembled a defensible end-to-end food waste circular economy platform with genuine operational switching costs, but its $1B+ Series C valuation implies revenue well above two-facility run-rate reality and complete financial opacity precludes independent underwriting, warranting a track posture pending disclosure.

Valuation

$1B

Alloy Therapeutics

Alloy Therapeutics looks strategically relevant and partner-rich, but the current $1.0B mark already assumes durable economics that public disclosures do not yet substantiate.

Valuation

$1B

vVardis

vVardis has created a genuinely novel dental therapeutic category with rapid US institutional adoption and unicorn-level backing, but the complete absence of disclosed financials and persistent insurance reimbursement gaps support only a research-more stance until an S-1 filing provides the evidence needed to underwrite the $1B+ private-market valuation.

Valuation

$1B

Vi Labs

Vi Labs is a qualified BUY as a leading enterprise AI platform for healthcare data intelligence, supported by a $1.64B valuation, a 190M-record data moat, and 100+ enterprise customers, tempered by undisclosed financials.

Valuation

$1.6B

Talos

Talos is a strategically strong institutional digital asset infrastructure platform with credible product breadth and customer traction, but its current valuation already prices in substantial future execution while public disclosure remains too thin for high-conviction underwriting.

Valuation

$1.5B

Revenue run-rate

$45.5M

Growth

67%

Advance Intelligence Group

Advance Intelligence Group is one of the most advanced SEA fintech multi-product platforms at profitability inflection, but undisclosed credit quality and an uncertain IPO path make this a conditional accumulate at or below the 2021 round valuation.

Valuation

$2B

Revenue run-rate

$500M

Growth

50%

Octane

Octane is a profitable, high-growth specialty fintech lender with a defensible moat in powersports and recreational markets; the $1.3B valuation is fair given GAAP profitability and 29% originations growth, making this a buy for specialty fintech investors with medium confidence pending full financial disclosure.

Valuation

$1.3B

Revenue run-rate

$400M

Growth

29%

Spirit AI

Spirit AI has stronger technical and partner proof than most young embodied-AI startups, but the public record still does not justify underwriting the current valuation without deeper financial diligence.

Valuation

$1.4B

Transmit Security

Research-more: Transmit Security has credible enterprise product and customer proof, but its private valuation is still too opaque and too rich to underwrite comfortably from public evidence alone.

Valuation

$2.7B

ARR

$33.4M

Genki Robotics

Genki Robotics combines elite founder pedigree and strong Japan robotics tailwinds, but the current $1 billion Series A price materially outruns public proof on product, customers, and economics.

Valuation

$1B

Valar Atomics

Valar is one of the fastest-moving U.S. advanced-nuclear startups, but public evidence still supports research-more rather than paying through its reported $2 billion 2026 mark.

Valuation

$2B

Hermeus

Hermeus has real proof of life—Mach 1.21 flight, a $219 million DIU-backed defense pathway, and a blue-chip investor set—but it is still pre-production, economically opaque, and dependent on difficult Mach 3 / payload-release and acquisition-transition milestones, so the prudent stance is research-more rather than buy.

Valuation

$1B

CMBlu Energy

CMBlu combines credible long-duration storage differentiation and strategic capital with a valuation that currently runs ahead of commercial proof, supporting a research-more call rather than a buy.

Valuation

$1.2B

Revenue run-rate

$1M

Black Lake Technologies

Black Lake appears to have real product-market fit in China's cloud manufacturing software niche and a credible industrial-AI upsell story, but the company still discloses too little about revenue quality, retention, and cap-table terms to justify an invest-now call at its April 2026 private-market valuation.

Valuation

$1.3B

Growth

60%

Judi Health

Judi Health is building a structurally differentiated transparent PBM and unified claims platform at meaningful scale, but the $3.25B September 2025 valuation prices in substantial admin-fee revenue growth that has never been publicly disclosed, warranting a Track stance with medium conviction pending confirmation of unit economics.

Valuation

$3.3B

Revenue run-rate

$3.7B

Growth

75%

Alpaca

Differentiated brokerage infrastructure asset with a credible self-clearing moat and rapid ARR growth, but private opacity on margins, concentration, and the cap table prevents a conviction buy at the $1.15B mark.

Valuation

$1.2B

Revenue run-rate

$100M

ARR

$100M

Growth

150%

Quince

Quince's M2C model and >$1B revenue milestone are genuinely impressive, but the $10.1B Series E implies a 5–10x EV/revenue multiple the public record cannot support and active deceptive-pricing litigation adds binary legal risk — warranting a track stance until margin data and litigation resolution improve underwriting visibility.

Valuation

$10.1B

Revenue run-rate

$2B

Svante Technologies

Svante holds the world's only solid-sorbent carbon-capture filter gigafactory and the strongest strategic investor syndicate in its category, but is pre-revenue with all commercial projects pre-FID and no disclosed financials, warranting a research-more stance pending FID confirmations and greater disclosure.

Photonic

Photonic has one of Canada's most credible private quantum architecture stories, but the public evidence still supports follow-up diligence more than price-insensitive conviction at a $2.0 billion mark.

Valuation

$2B

OnlyFans

OnlyFans is a dominant and highly profitable creator-payments platform, but the current price already reflects material regulatory, payment, and governance risk.

Valuation

$3.2B

Revenue run-rate

$1.4B

Enter

Enter is the dominant AI-powered mass-litigation platform for Brazil's uniquely vast legal market, growing at exceptional speed with blue-chip customers and Tier-1 investors, but carrying key-person and market-concentration risk as it attempts global expansion.

Valuation

$1.2B

Botshare

Botshare addresses a real adoption pain point in robotics, but the company is too young and too lightly disclosed to justify strong conviction at a unicorn valuation.

Valuation

$966M

Agilink

Agilink shows unusually strong early commercialization and investor pull for a dexterous-hand startup, but thin disclosure, parent dependence, and a stretched $1B+ valuation justify a research-more stance.

Valuation

$1B

RADAR

RADAR has genuine first-mover scale and compelling customer proof in retail RFID, but the $1B price cannot be validated without ARR, gross margin, or NRR disclosure.

Valuation

$1B

Guangdong Tianji Intelligent System Co., Ltd.

Tianji has real commercial momentum and technical differentiation, but sparse financial disclosure and a stretched unicorn valuation make it a track-not-buy story for new capital today.

Rain

Rain has built a genuinely differentiated stablecoin payments infrastructure platform with rare dual-network card membership and striking growth metrics, but the $1.95B valuation demands revenue disclosure that remains absent, and Mastercard's acquisition of BVNK is a direct competitive threat that could reshape enterprise pipeline dynamics.

Valuation

$2B

LumApps

LumApps has built a credible AI employee hub at genuine enterprise scale with $150M combined ARR and Bridgepoint sponsorship, but private-company opacity, Beekeeper integration risk, and a stretched >$1B valuation limit confidence to a track stance until NRR and gross margin are disclosed.

Valuation

$1B

Revenue run-rate

$150M

ARR

$150M

Growth

30%

Amca

Amca has a credible industrial thesis and meaningful early scale, but the $1B-plus mark is hard to underwrite without audited financials or customer-concentration disclosure.

Valuation

$1B

Moneyview

Moneyview has enough scale, profit, and IPO readiness to stay on the active watchlist, but DLG exposure, partner concentration, and incomplete durability disclosure keep the right stance at track rather than buy.

Valuation

$1.2B

Revenue run-rate

$379M

Growth

74%

GI WaaS

GI WaaS has credible wastewater-treatment activity and Saudi market tailwinds, but the reported unicorn valuation outruns the quality of its public disclosure.

Valuation

$1B

Decart

Decart has built rare momentum in real-time world models and AI infrastructure, but the current ~$4 billion valuation is ahead of what the public revenue record can yet support.

Valuation

$4B

Yinwang

Yinwang is strategically important and clearly scaling, but its RMB 115 billion mark already prices in a great deal of upside before standalone economics are publicly provable.

Valuation

$16B

Growth

474.4%

Ninja

Ninja has achieved unusually fast Saudi quick-commerce scale and a credible pre-IPO profile, but incomplete disclosure on revenue quality, margins, and governance keeps the current $1.5 billion mark in track-not-buy territory.

Valuation

$1.5B

K2 Space

Track: K2 Space has stronger contract proof and more differentiated product ambition than most private satellite manufacturers, but the $3 billion entry price still requires on-orbit validation, manufacturing execution, and much better financial transparency.

Valuation

$3B

Galbot

Galbot is a strategically credible but financially opaque Chinese humanoid robotics leader with real industrial deployments, world-class embodied AI, and state-backed capital — warranting close research and diligence before a commitment.

Valuation

$3B

Zap Energy

Zap Energy has moved beyond a slideware fusion story with credible plasma, systems, and DOE-reviewed plant-engineering progress, but the 2026 fusion-plus-fission expansion widens commercialization, licensing, and financing risk before customers, economics, or current price discovery are visible.

Xiamen Hithium Energy Storage Technology Co., Ltd. (Hithium)

Hithium has become a scaled global ESS battery contender with credible shipment and revenue momentum, but current public evidence supports a track stance rather than a buy because valuation clarity, litigation exposure, receivables quality, and IPO-readiness disclosure remain too thin.

Valuation

$3.5B

Revenue run-rate

$1.8B

Growth

26%

Kpler

Kpler is a category-defining physical trade intelligence platform with a hard-to-replicate AIS data moat, confirmed rapid ARR growth, and 12,000+ enterprise customers—but the June 2026 Sixth Street entry at an implied 13–20x ARR multiple is stretched relative to public data-analytics peers, and zero disclosed unit economics (NRR, gross margin, churn) combined with the UK CMA antitrust review and a co-founder leadership transition prevent a buy call.

Valuation

$4B

eSentire

Forrester EU Wave Leader MDR pureplay at the low end of the public-comp band, with the 2-year stalled Evercore sale process and rising Microsoft / CrowdStrike bundling pressure as the dominant adverse signals — MONITOR with conditional INVEST on sale-process close at base case plus NRR ≥95% and top-10 channel partner ARR <40%.

Valuation

$1B

Revenue run-rate

$150M

ARR

$150M

Flexiv Ltd.

Flexiv is a credible Stanford-pedigreed adaptive-robotics franchise with a differentiated force-control stack and unicorn financing, but private disclosure and US-China geopolitics keep the valuation hard to defend.

Valuation

$1B

Preferred Networks, Inc.

Preferred Networks remains Japan's most credible vertically integrated AI platform, but a thinly disclosed revenue base and a conflicted ($1.0B vs $2B+) third-party valuation make the headline unicorn price hard to underwrite from public evidence alone.

Valuation

$2B

Revenue run-rate

$42M

X-energy

X-energy has assembled a uniquely deep advanced-nuclear package — Xe-100 HTGR plus TRISO-X fuel, DOE ARDP cost-share, Dow + Energy Northwest + Amazon offtake, an 11 GW orderbook narrative, and a fresh Nasdaq listing — but with no Xe-100 reactor yet built, Q1 2026 opex running ~2.5x revenue, undisclosed reactor economics, and a long licensing and FOAK construction path ahead, current valuation is a probability-weighted strategic option rather than a defensible cash-flow story, and the appropriate stance is research-more with attractive optionality and high execution risk.

Growth

109%

You.com

You.com has credible product breadth, customer proof, and capital access, but public evidence still underwrites relevance more convincingly than durable economics, leaving the $1.5B Series C mark looking stretched.

Valuation

$1.5B

Modal

Modal has earned a track call by demonstrating $300M ARR with 5x growth in seven months, a diversified high-quality customer roster, and a technically differentiated serverless platform with Sandbox revenue exceeding one-third of total ARR — but the 15.5x ARR multiple is stretched, three major outages in May–June 2026 signal reliability risk, and complete opacity on gross margin and NRR prevents a buy call at the current price.

Valuation

$4.7B

Revenue run-rate

$300M

ARR

$300M

Harmonic

Harmonic is the leading formal-mathematics AI company, holding benchmark records at the IMO and VERINA level, but faces unproven monetization and a concentrated key-person risk from Vlad Tenev's concurrent Robinhood CEO role.

Valuation

$1.5B

Fireworks AI

A top-tier AI-inference asset with elite founders and hypergrowth, priced for perfection against ~50% margins and structural commoditization risk.

Valuation

$4B

Revenue run-rate

$800M

Clay

Clay has achieved exceptional product-market fit, capital efficiency, and community moat at $100M ARR, but the $5B tender-implied valuation embeds unverified NRR and gross-margin assumptions that prevent a conviction buy without data-room access.

Valuation

$5B

Revenue run-rate

$100M

ARR

$100M

Vuori

Vuori appears to be a genuinely strong and profitable premium activewear brand, but the last $5.5B mark still looks too expensive to underwrite confidently without audited financial disclosure.

Valuation

$5.5B

Revenue run-rate

$1B

Vantaca

Vantaca appears to be a category leader in HOA/community-management software with credible growth, real product breadth, and a validated 2025 financing anchor, but public disclosure is still too thin to justify an aggressive underwrite at the last unicorn valuation.

Valuation

$1.3B

Growth

95%

Ricursive Intelligence

Ricursive combines rare AlphaChip-derived technical credibility with extraordinary financing speed, but the company still lacks public customer, revenue, and benchmark proof sufficient to fully underwrite a $4B valuation.

Valuation

$4B

HistoSonics

HistoSonics has rare private-medtech proof for a first-of-kind non-invasive tumor platform, but missing commercial economics and a full 2025 valuation anchor leave it in research-more territory rather than justify fresh capital at current terms.

Valuation

$2.3B

Higgsfield

Higgsfield has real hypergrowth and product-market pull in AI video marketing workflows, but the current underwriting case is constrained by unresolved safety, governance, and quality-of-revenue risk.

Valuation

$1.3B

Revenue run-rate

$200M

ARR

$200M

Standard Bots

Research-more: Standard Bots has a credible AI-native cobot product narrative and real customer anecdotes, but the June 2026 $1B valuation is too price-sensitive to underwrite from public evidence because revenue, margins, and deployment efficiency remain undisclosed.

Valuation

$1B

Modular

Modular has real technical differentiation, fresh capital, and early customer proof, but public revenue, margin, retention, and cap-table disclosure remain too thin to underwrite a buy at the latest $1.6 billion valuation.

Valuation

$1.6B

Code Metal

Code Metal has a differentiated verification-first product and credible defense and industrial demand signals, but at the disclosed $1.25B Series B price the public KPI record is still too thin to underwrite without more diligence.

Valuation

$1.3B

Neuralink

Neuralink is the flagship invasive BCI platform with credible clinical and financing momentum, but absent public economics, unresolved reimbursement and long-term support dependencies, and a stretched ~$9B-$9.6B valuation anchor keep the name in research-more territory.

Valuation

$9B

LogicMonitor

LogicMonitor is a credible scaled observability asset with fair public valuation support, but unresolved capital-structure opacity, incomplete unit-economics disclosure, and residual security/reliability trust debt keep the recommendation at TRACK rather than BUY.

Valuation

$2.4B

ARR

$400M

Erebor

Erebor targets a credible post-SVB startup-banking gap, but its public operating proof still trails its multibillion-dollar valuation.

Valuation

$4.4B

ShopMy

ShopMy has built a credible, fast-scaling creator-commerce platform with real platform-sales and profitability signals, but the public record still supports only a track stance because the latest $1.5 billion valuation sits ahead of disclosed fundamentals and detailed financing terms.

Valuation

$1.5B

Growth

200%

Legora

Legora has category-leading growth in legal AI, but the current valuation already prices in a large share of the upside.

Valuation

$5.6B

ARR

$100M

Genspark

Genspark's pivot from AI search to agentic workspace is compelling, but public disclosure still lags the valuation narrative.

Valuation

$1.6B

Revenue run-rate

$200M

FieldAI

FieldAI combines elite field-robotics talent, strong investor validation, and a differentiated hardware-agnostic embodied AI stack, but the lack of audited financial disclosure and limited named customer proof make the $2B valuation difficult to underwrite from public evidence alone.

Valuation

$2B

Wonder

Wonder has assembled a credible multi-surface mealtime platform, but public evidence is still too thin on standalone economics and post-acquisition integration quality to underwrite confidently above the reported $7B valuation.

Metropolis

Metropolis has real scale, operational reach, and product optionality, but the current $5B valuation still looks stretched until EBITDA quality, leverage reduction, and regulatory overhang are materially de-risked.

Valuation

$5B

Fal

Fal is the leading infrastructure layer for generative media inference, with extraordinary revenue growth, a clear developer moat, and a $4.5B valuation backed by top-tier investors — but faces intense competition and unverified financial disclosures.

Valuation

$4.5B

Revenue run-rate

$95M

Coralogix

Coralogix has real product breadth, customer traction, and funding momentum, but the public record is still too thin on revenue quality, retention, and cap-table terms to justify aggressive underwriting at the $1.6B mark.

Valuation

$1.6B

Revenue run-rate

$160M

Bending Spoons

Bending Spoons looks like a real software compounder with rare scale and recurring-revenue quality, but leverage, incomplete segment disclosure, and recurring user-trust backlash keep the right call at research-more until the IPO file is fuller and priced.

Valuation

$11B

Revenue run-rate

$2.4B

Growth

132.2%

NRR

95%

Startorus Fusion

Startorus Fusion looks like one of China's more credible private fusion platforms, but the current unicorn valuation still depends more on milestone delivery, policy support, and future disclosure than on proven commercial traction.

Valuation

$1B

team.blue

team.blue is Europe's best-capitalised SMB digital platform with a proven buy-and-build flywheel and Tier-1 PE backing, but complete financial opacity, a failed leveraged loan repricing, and a valuation multiple that implies a 3–5× premium to public European peers limit conviction to a "track" rating until the debt structure and revenue base are independently confirmed.

Valuation

$5.2B

Skyroot Aerospace

Skyroot has real technical progress, capital backing, and manufacturing ambition, but the orbital launch, customer, and unit-economics proof still trails the current $1.1B valuation.

Valuation

$1.1B

Tandem Technology

Forus has built a real prescription-access network with strong growth and strategic value, but the reported $1B valuation remains hard to underwrite without margin, concentration, and governance disclosure.

Valuation

$1B

Revenue run-rate

$50M

EGYM

EGYM is an EBITDA-profitable global fitness-technology platform with $800M+ combined 2025 revenue, 75% subscription mix, and genuine network effects, but the 9.4× combined EV/revenue multiple is stretched versus public comps, and key underwriting drivers—NRR, gross margin, and post-integration unit economics—remain undisclosed in a fully illiquid private vehicle.

Valuation

$1.2B

Hive Box

Hive Box has unmatched domestic smart-locker density and early profit improvement, but unresolved redemption litigation, consent-driven regulatory pressure, and a stale 2024 private mark keep the case in watchlist territory.

Valuation

$3.5B

Revenue run-rate

$640M

Growth

33.6%

Rebel Foods

Rebel Foods is a scaled, strategically relevant food-tech platform, but the public evidence still supports a price-sensitive watchlist posture rather than a conviction buy at the old unicorn mark.

Valuation

$1.4B

Revenue run-rate

$170M

Growth

19%

Infinium

Infinium has stronger public customer and sponsor proof than most electrofuels peers, but the current public record still supports a watchlist posture because price, plant economics, and delivered-volume evidence remain too opaque for a conviction entry call.

Kailera Therapeutics

Kailera is one of the best-capitalized public obesity biotechs and already has unusually strong precommercial efficacy positioning, but public investors still need global Phase 3 confirmation before the valuation case graduates from a catalyst-driven track posture to a clear buy.

Valuation

$2.1B

Eve

Attractive category position and customer proof, but public evidence still supports research-more rather than a fresh aggressive entry because revenue support is opaque and the prior valuation already prices in a large share of the upside case.

Valuation

$1B

Deepgram

Deepgram appears to be a credible category leader in real-time voice AI, but the current $1.3B mark looks worth monitoring rather than aggressively underwriting until private financial denominators are disclosed.

Valuation

$1.3B

Assured Insurance Technologies

Assured looks strategically credible in AI claims automation, but incomplete public operating disclosure and a full unicorn price keep the investment posture at research-more rather than buy.

Valuation

$1B

Basis

Basis appears to be a real category leader in agentic accounting automation, but the current valuation is ahead of what public economics can support.

Valuation

$1.2B

Kitopi

Interesting scaled operator, but public evidence supports caution because valuation still looks expensive relative to visible peers and visible disclosure.

Valuation

$1.6B

Revenue run-rate

$165.7M

Growth

32%

Xpansiv

Xpansiv looks like strategically important climate-market infrastructure with credible unicorn price support and real workflow breadth, but persistent financial and cap-table opacity plus a fragile voluntary-carbon backdrop keep the correct public-markets posture at research-more.

Valuation

$1.4B

Sonatype

Sonatype appears to be a credible, profitable software-supply-chain control-plane asset with strong regulated-enterprise proof, but private-equity opacity, bundled-platform competition, and incomplete debt and retention disclosure keep the report in research-more territory.

Revenue run-rate

$150M

ARR

$150M

Loggi

Research-more: Loggi is a real, scaled Brazilian last-mile platform with credible breakeven levers, but the stale ~US$2B private valuation anchor and thin disclosure make the current case too price-sensitive to underwrite publicly.

Valuation

$2B

Pleo

Pleo shows real product breadth, scale, and monetization progress, but the supportable public-data conclusion remains research-more because the latest mark still looks stretched against disclosed evidence and too many underwriting-critical operating metrics remain private.

Valuation

$1.6B

Revenue run-rate

$150M

Tipalti

Tipalti is a real scaled fintech platform with broad product depth and strong customer adoption, but the combination of regulated payments exposure, debt-funded expansion, layoffs, and a stale 2021 valuation anchor makes this a research-more name until management proves current economics and fair value.

Valuation

$8.3B

ARR

$200M

Fresha

Fresha has enough scale, product breadth, and profitability signal to merit active tracking, but public disclosure is still too thin and the >$1B mark looks stretched for a fresh buy.

Valuation

$1B

Revenue run-rate

$140M

Growth

60%

Retro Biosciences

Retro has credible science, elite backers, and a real first-in-human milestone, but public evidence still supports a research-more stance because the $1.8 billion pre-money mark is ahead of disclosed efficacy, economics, and commercial proof.

Valuation

$1.8B

MiRus

MiRus has unusually strong strategic validation for a private medtech company, but the current price still depends on pivotal-trial success and private financial facts that public evidence does not yet supply.

Valuation

$4.4B

Luma AI

Luma AI has documented product traction and a credible $4B private mark from a sovereign-backed investor, but zero revenue disclosure means the valuation cannot be underwritten confidently from public evidence alone.

Valuation

$4B

Hark

Hark has elite founder pedigree, capital, and compute access, but the public record still supports an avoid stance because a $6 billion Series A valuation is ahead of disclosed customer, product, and economic proof.

Valuation

$6B

Robot Era

Robot Era has stronger public deployment and financing proof than most humanoid startups, but the current mark still looks investable only with more diligence because commercialization quality and economic disclosure lag the valuation narrative.

Sunday

Sunday pairs a differentiated real-home data loop and elite robotics pedigree with blue-chip financing, but the public record still lacks the price, customer proof, and unit economics needed to underwrite the $1.15 billion valuation.

Valuation

$1.2B

HIF Global

HIF Global has real operating proof and unusually strong strategic backers, but public evidence still supports a research-more stance because commercial-scale execution, economics, and current price discovery remain too opaque.

Govini

Govini looks investable because it has crossed meaningful ARR scale and built a real DoD software moat, but conviction is capped by sparse disclosure on retention, concentration, and unit economics.

Valuation

$1.3B

ARR

$100M

Advanced Navigation

Advanced Navigation appears to be a real, strategically relevant assured-PNT company, but the public record still does not support paying a late-stage unicorn-style price with confidence.

Performance Drone Works

Performance Drone Works shows credible defense-market traction, product breadth, and manufacturing ambition, but public evidence is still insufficient to price the business confidently because revenue, backlog, margin, headcount, and post-money terms remain opaque.

Valuation

$730M

Goodfire

Goodfire looks like a category-defining interpretability company, but the public record still does not justify underwriting the February 2026 valuation as a clear bargain.

Valuation

$1.3B

SpreeAI

SpreeAI shows credible product, partner, and brand momentum, but public economics are too thin to justify the reported $1.5B valuation with conviction.

Valuation

$1.5B

Lovable

Lovable has rare growth velocity, a compelling prompt-to-production product wedge, and real enterprise signal, but public evidence still does not support buy-grade confidence at current prices because enterprise mix, retention, margins, headcount, and cap-table terms remain too opaque relative to the valuation climb.

Valuation

$6.6B

Revenue run-rate

$500M

Periodic Labs

Periodic Labs combines one of the strongest founder teams in frontier AI and materials science with an ambitious autonomous-lab thesis and exceptional investor validation, but the company remains far from commercially proven and the reported 2026 financing mark prices in success well before public revenue or customer evidence justifies it.

Valuation

$7.5B

Aalyria

Real multi-orbit orchestration proof and a credible government-commercial wedge, but the $1.3B round already prices in software-like upside ahead of disclosed economics.

Valuation

$1.3B

Render

Render has real product breadth, strong developer adoption, and a credible AI-native wedge, but public monetization evidence remains too thin to comfortably underwrite its $1.5B valuation.

Valuation

$1.5B

Rhoda AI

Compelling physical-AI thesis with elite backing, but too little commercial disclosure to underwrite the $1.7B mark confidently.

Valuation

$1.7B

Oxide Computer Company

Deep technical moat, credible federal and financial-services wedge, but no disclosed revenue or valuation makes underwriting the $389M capital base speculative at any price.

Mind Robotics

Mind Robotics has a rare industrial data and capital wedge, but public proof still lags its multibillion-dollar valuation.

Valuation

$3.4B

Zenobe Energy

Zenobē has real sponsor backing, operating proof, and infrastructure-scale relevance, but the public record is still too thin on economics and equity terms to underwrite a precise price.

Pivot Bio

Pivot Bio has genuine agronomic proof and meaningful commercial reach, but opaque economics, regulatory uncertainty for next-generation products, and a stretched current mark keep the name in research-more territory.

Valuation

$1.7B

Feedzai

Strategically relevant AI-native financial crime platform, but the current valuation is difficult to underwrite without private revenue, retention, and term data.

Valuation

$2B

BetterUp

BetterUp has credible enterprise product-market fit and meaningful scale, but limited disclosure and a still-demanding late-stage valuation argue for continued diligence rather than immediate conviction.

Valuation

$2.3B

Revenue run-rate

$215M

ARR

$215M

Growth

41%

Allen Control Systems

ACS has unusually strong early military proof for a young counter-UAS startup, but the $2.2B Series B is ahead of public economic disclosure.

Valuation

$2.2B

N26

N26 has re-established growth and a credible path to sustainable profitability, but ongoing supervisory pressure and stale private-market price discovery make the current valuation case investable only with caution.

Valuation

$6B

Growth

40%

Darwinbox

Darwinbox shows real enterprise HCM momentum and a plausible path to $100M ARR, but public evidence still supports a TRACK / stretched stance rather than a clear buy at current pricing.

Valuation

$950M

Revenue run-rate

$100M

ARR

$100M

Growth

58%

OfBusiness

OfBusiness is a real scaled and profitable industrial B2B commerce-plus-finance platform, but without fresh parent audits and a public DRHP it is only worth tracking near the roughly $4 billion secondary anchor, not the floated $6-9 billion IPO range.

Valuation

$4B

Growth

25.7%

HomeLight

HomeLight has built a real multi-product residential transaction platform with meaningful reach and credible customer pain-point fit, but opaque current financials, capital-sensitive product mix, regulatory exposure, and a post-2022 valuation reset keep the recommendation at research-more.

Valuation

$1.1B

Hightouch

Hightouch is a real late-stage winner in warehouse-native marketing software, but the $2.75B Series D looks too expensive to underwrite from public evidence alone.

Valuation

$2.8B

ARR

$100M

Carbon

Carbon has real production-scale DLS proof and insider-backed runway, but opaque financials and a stale $2.4B valuation anchor make further diligence—not underwriting at face value—the right posture.

Valuation

$2.4B

Highview Power

Highview holds a credible strategic position in UK long-duration energy storage, but valuation remains under-determined until Carrington proves commercial execution and private financing terms become clearer.

ICON

ICON has real technical and deployment proof, but the public record is still too thin to justify paying anywhere near the old ~$2B mark with confidence after layoffs and a much smaller, valuation-undisclosed Series C.

Zepz

Zepz is a real scaled remittance incumbent with strong corridor coverage and product optionality, but public-only underwriting remains weak because valuation, governance, and financial disclosure have not kept pace with its private-market history.

Valuation

$5B

Gusto

Gusto is a buy at $9.3B: $1B+ actual revenue, FCF-positive, accelerating growth, and a 9x multiple that is materially discounted vs. Rippling and Deel—positioning it for significant IPO upside when markets reopen.

Valuation

$9.3B

Revenue run-rate

$1B

ARR

$1B

Growth

30%

Story Protocol

Story Protocol has credible technical differentiation and real AI/IP narrative tailwinds, but public evidence still supports only a research-more stance because revenue, enterprise adoption, and legal enforceability remain unproven while valuation looks stretched versus token-market and usage signals.

Valuation

$2.3B

SKIMS

SKIMS has reached real global brand scale and category relevance, but the current $5 billion private valuation already prices in continued hypergrowth while audited financials, governance detail, and celebrity-concentration risk remain unresolved.

Valuation

$5B

Revenue run-rate

$1B

Growth

50%

Sidecar Health

Sidecar Health has a differentiated transparent-plan model and real strategic validation from Koch, but the company still withholds the underwriting, scale, and cap-table data needed to price the risk with conviction.

CHAOS Industries

CHAOS is a serious distributed-radar defense startup with real procurement-path signals, but the public record is still too thin on revenue quality and customer economics to support the latest price without more diligence.

Valuation

$4.5B

Versa Networks

Versa Networks is a credible late-stage unified-SASE platform with meaningful channel and customer traction, but opaque financial disclosure, execution complexity, and a still-debatable 2024 valuation keep the current stance at research-more rather than buy.

Valuation

$1.5B

Revenue run-rate

$147.9M

Forus

Forus appears to be a real and strategically valuable prescription-access workflow asset, but the public evidence is still too thin to justify paying the current unicorn valuation with conviction.

Valuation

$1B

Revenue run-rate

$50M

Solace Health

Solace has built a compelling, reimbursement-backed patient-advocacy platform with real national scale, but the public record still supports only a track stance because core economics, payer mix, and Series C terms remain too opaque for a clean late-stage underwrite.

Positron AI

Positron has credible early proof—real financing, named lighthouse customers, and a differentiated memory-first product roadmap—but at a $1B+ entry price with undisclosed revenue, margins, and security terms, the prudent stance is to track rather than underwrite the round as clearly attractive.

Valuation

$1B

Harmattan AI

Harmattan AI has assembled unusually strong sovereign-defense proof points for a two-year-old startup—dual MoD Programs of Record and a Dassault Rafale F5 partnership—but the lack of public financial disclosure keeps the investment case in research-more territory.

Valuation

$1.4B

Dexory

Dexory has credible product differentiation, real customer traction, and strong investor support, but the public evidence still supports only a research-more stance because valuation and software-like economics remain under-disclosed.

Quantexa

Quantexa is a scaled and strategically relevant Decision Intelligence platform, but public evidence supports TRACK rather than BUY until private diligence closes gaps on exact ARR, margin quality, burn, and the late-stage preference stack.

Valuation

$2.6B

ARR

$100M

NRR

120%

Axiom Space

Axiom Space is strategically important and has real execution proof, but the public file is still too thin to justify paying the 2026 rebound mark as clean common equity.

1KOMMA5°

1KOMMA5° has real scale and plausible software upside, but public evidence still supports a RESEARCH-MORE stance because valuation support, preference terms, and realized Heartbeat economics remain too thin for a conviction buy.

Growth

15.6%

Starling Bank

Starling is one of the few profitable European neobanks, but public evidence supports a TRACK rather than BUY stance until post-fine regulatory rehabilitation, FY2026 profit recovery, and clearer Engine economics are visible.

Valuation

$5B

Salt Security

Salt Security remains a credible API security category pioneer with meaningful enterprise traction, but the gap between public operating disclosure and the 2022 unicorn valuation is still too large for a high-conviction investment call.

Valuation

$1.4B

ARR

$75M

Growth

54%

Avathon

Avathon has credible industrial AI product breadth, government traction, and sector-specific customer proof, but unresolved financial opacity and conflicting valuation signals make it a research-more opportunity rather than an invest-now conviction call.

Valuation

$1.4B

Aurora Solar

Aurora Solar appears to be a genuine category leader in solar workflow software, but public evidence still points to stretched valuation, market-driven operating pressure, and too much missing financial disclosure to underwrite the company confidently at its benchmark.

Valuation

$4B

ARR

$130M

Mambu

Mambu appears to be a real, strategically relevant cloud-banking and payments infrastructure platform, but the lack of current financial disclosure leaves the public investment case attractive only at a meaningfully lower entry point or after deeper private diligence.

Valuation

$5.5B

Uzum

TRACK: Uzum has credible national scale, ecosystem breadth, and reported profitability, but the current $2.3 billion reference point looks fair-to-stretched for new common equity until valuation terms and segment economics are cleaner.

Valuation

$2.3B

Upgrade

Profitable multi-product consumer-credit platform with meaningful scale, but the 2025 private mark already prices in a lot of future execution.

Valuation

$7.3B

Revenue run-rate

$1B

Faire

Faire has real marketplace scale and improving monetization breadth, but public evidence is still too thin on credit losses, margin structure, and partner dependency to justify more than a track posture at the current valuation.

Valuation

$5.2B

Revenue run-rate

$500M

Growth

32%

NRR

110%

Ascend Money

Research more: Ascend Money has real scale, strategic sponsorship, and Thai virtual-bank upside, but valuation above the last $1.5 billion public anchor looks stretched until audited economics and current price discovery are disclosed.

Valuation

$1.5B

GrubMarket

GrubMarket has built a rare scaled hybrid of food distribution and vertical ERP software, but the SEC's revenue-overstatement settlement, acquisition-roll-up complexity, and still-thin audited disclosure make the current price a watchlist story rather than a buy today.

Valuation

$4.5B

Revenue run-rate

$2.4B

Growth

20%

Outschool

Outschool appears to be a real, scaled K-12 live-learning marketplace, but public evidence does not justify underwriting the 2021 $3B mark without private financial and retention data.

Valuation

$3B

Fireblocks

Fireblocks is a real institutional digital asset infrastructure leader with verifiable enterprise scale, but the unchanged $8B Series E mark is indefensible at current 4–6x EV/revenue multiples implied by BitGo's IPO and Anchorage's financing, and the company's continued opacity on margins, NRR, and litigation resolution makes a research-more call the only defensible position.

Valuation

$8B

Calm

Calm is a scaled and durable mental-wellness brand with real consumer and sponsor reach, but private-company opacity, leadership-transition risk, and a stale 2020 US$2 billion valuation anchor keep the current stance at track rather than buy.

Valuation

$2B

Zelos

Zelos appears to be a real, unusually scaled autonomous-logistics operator with strong partner-backed deployment proof, but hidden economics, mixed valuation reporting, and unresolved legal/governance questions keep the case in research-more territory.

Valuation

$1.4B

Nirvana Insurance

Nirvana shows credible AI-native underwriting momentum and fresh Series D backing, but public disclosure is still too thin to underwrite the $1.5 billion valuation with conviction.

Valuation

$1.5B

Epirus

Epirus has credible Army proof and strong counter-drone tailwinds, but its likely down-round reset, opaque economics, and prime-backed competition keep the investment stance at track rather than buy.

Tempo

Tempo combines elite strategic sponsorship and a credible stablecoin-payments product thesis with unusually thin public monetization and governance evidence, so the right stance remains research-more rather than paying up at the last reported valuation.

Valuation

$5B

Tala Health

Powerful backers and a credible payer pain point are real positives, but Tala's public evidence is too thin to justify its $1.2B entry price today.

Valuation

$1.2B

NewLimit

New Limit combines elite capital access and unusually detailed preclinical progress with no human data, making it a high-upside but still high-risk research-more opportunity at the current price.

Valuation

$3.1B

Boom Supersonic

Boom Supersonic holds the most credible post-Concorde supersonic aviation position — with 130 aircraft pre-orders, a June 2025 regulatory tailwind from the overland ban repeal, and proven XB-1 aerodynamics — but remains pre-revenue and a decade from commercial service, making this a high-risk speculative position appropriate only for patient strategic capital.

Valuation

$1.5B

Mach Industries

Mach Industries has credible defense-autonomy momentum, real manufacturing ambition, and enough Army-linked proof to stay on the radar, but weak revenue-quality disclosure and a stretched $1.8 billion Series C keep the name in TRACK rather than buy territory.

Valuation

$1.8B

Cast AI

Cast AI delivers measurable cloud savings and AI-infrastructure optionality, but undisclosed revenue and round economics keep the unicorn valuation from looking clearly underwritten.

Valuation

$1B

Voodoo

Voodoo has rare private-company scale and confirmed profitability, but opaque unit economics, B-rated leverage, and an unproven BeReal bet make this a track / research-more at any premium multiple.

Valuation

$2.6B

Revenue run-rate

$778M

Growth

16%

Varda Space Industries

Varda has exceptional operational proof and a genuine dual-use platform, but the $1.58 billion Series D price requires private financial disclosure to underwrite at medium confidence and high risk.

Valuation

$1.6B

Lunar Energy

Lunar is a real integrated battery and Gridshare VPP platform with meaningful traction and capital access, but opaque economics, California- and partner-heavy exposure, and conflicting valuation signals keep the right call at research-more.

Trulioo

Trulioo is a high-quality global identity platform with re-accelerating revenue growth and strong enterprise proof, but the 4-year-stale $1.75B valuation anchor, unaudited financials, and leadership transition support a track rather than buy posture.

Valuation

$1.8B

Revenue run-rate

$150.6M

ARR

$150.6M

Growth

29%

Loadsmart

Loadsmart has credible platform breadth and improving operating discipline, but limited financial disclosure, freight-cycle sensitivity, and stale unicorn pricing keep the investable call at research-more.

Valuation

$1.3B

Revenue run-rate

$108M

Xendit

Xendit is a credible regional payments infrastructure winner with real scale and product breadth, but opaque current economics, concentration, and regulatory or operational exposure keep the recommendation at research-more and make premium pricing above the unicorn floor look stretched.

Valuation

$1B

Rokt

Rokt merits tracking at the US$3.5 billion secondary valuation because public evidence supports scale, growth, and strategic breadth, but private-company opacity prevents a higher-conviction underwriting call.

Valuation

$3.5B

Revenue run-rate

$600M

Growth

43%

NRR

110%

GoodLeap

GoodLeap is a scaled category survivor, but the stale $12B private mark, ABS stress, live consumer-finance litigation, and limited private disclosure make the right action track / research-more rather than buy near the historical valuation.

Valuation

$12B

Revenue run-rate

$361M

Anaconda

Anaconda is a real, profitable Python platform with enterprise reach, but the public evidence still falls short of underwriting the last round with high conviction.

Valuation

$1.5B

ARR

$150M

Substrate

Substrate is pursuing a bold and strategically relevant U.S. lithography-and-foundry thesis, but the current public record still supports only a medium-confidence research-more stance: the company has fundraising momentum and intriguing technical signals, yet lacks customer, throughput, yield, and financing proof commensurate with its roughly $1 billion valuation.

Valuation

$1B

OnXmaps

OnX appears to have built a real, scaled outdoor-mapping subscription platform, but the public record still lacks enough revenue-quality, retention, and term disclosure to underwrite the July 2025 ~$1.4B valuation with conviction.

Valuation

$1.4B

Owner.com

Owner appears to have built a real and increasingly scaled restaurant-software platform for independent operators, but the public record still does not provide enough denominator detail on revenue quality, retention, margins, or financing terms to justify underwriting the May 2025 $1B valuation with conviction.

Valuation

$1B

Revenue run-rate

$81M

Invisible Technologies

Invisible Technologies has genuine enterprise AI traction and credible product breadth, but the latest >$2 billion price already assumes stronger forward growth and software-like economics than public evidence currently proves.

Valuation

$2B

Growth

123%

LangChain

LangChain is a category-defining agent engineering platform with real enterprise traction, but the last disclosed revenue range still falls far short of supporting the 2025 $1.25B price from public evidence alone.

Valuation

$1.3B

Revenue run-rate

$14M

ARR

$14M

Windsurf

Windsurf built a strategically valuable AI coding platform with real enterprise traction, but the independent company has effectively been broken into talent, technology, and successor-product components, eliminating a clean new equity entry.

Valuation

$1.3B

Revenue run-rate

$82M

ARR

$82M

Growth

105%

Vultr

Vultr has credible independent-cloud and GPU-infrastructure positioning plus real financing validation, but the public record is still too thin on revenue, margins, debt terms, and customer quality to justify a clean buy at its last $3.5B mark.

Valuation

$3.5B

Liquid AI

Liquid AI has differentiated edge-deployment technology and credible strategic backing, but the $2.3B private valuation still outruns the public commercial disclosure package.

Valuation

$2.3B

Lighthouse

Lighthouse looks like a category-leading hospitality software platform, but public evidence is still too thin on audited growth, retention, and capital-structure terms to support a full buy recommendation at the last unicorn mark.

Valuation

$1B

Garner Health

Garner appears to be a credible late-stage healthcare navigation winner with real scale and a differentiated data-and-incentives model, but the $2.74 billion Series E already prices in premium execution while public disclosure on margins, retention, and capital structure remains too thin for a clean buy call.

Valuation

$2.7B

Revenue run-rate

$200M

ARR

$200M

JSW One Platforms

JSW One Platforms has a credible full-stack industrial-commerce thesis and a strategically useful JSW Group moat, but the ~$1B valuation still depends on unaudited FY25 operating data and a fast- scaling credit/distribution model that carries meaningful execution and governance risk.

Valuation

$1B

Revenue run-rate

$478M

Growth

179.6%

GlossGenius

GlossGenius looks like one of the stronger beauty-vertical SMB software platforms in the U.S., but public evidence still leaves too much uncertainty on durability and economics to support more than a track posture at the unicorn valuation.

Valuation

$1.1B

ARR

$100M

Framer

Framer looks like a real design-led website-platform winner, but the current $2B valuation already prices in strong enterprise conversion and leaves too little disclosure on retention, margins, and revenue mix to justify an aggressive entry.

Valuation

$2B

Revenue run-rate

$50M

ARR

$50M

Verdiva Bio

Verdiva is one of the best-capitalized private oral-obesity startups, but public-only evidence still supports a track posture because the valuation already assumes meaningful clinical success while key efficacy, CMC, IP, and financing details remain opaque.

Valuation

$2.5B

Xpanceo

Xpanceo has assembled rare capital and a credible prototype engine around a potentially important post-screen interface, but the company is still years from a publicly validated commercial product and the last disclosed valuation already prices in milestones that remain unproven.

Valuation

$1.4B

Insider

Insider is a scaled global martech platform with credible product breadth and customer adoption, but limited public financial disclosure and a rich late-stage price reference argue for disciplined tracking rather than aggressive underwriting.

Valuation

$2B

Growth

36%

Degreed

Degreed has enough market relevance, customer proof, and product depth to merit continued diligence, but the public record is still too opaque on retention, runway, cap table, and current valuation to justify a buy recommendation in the tougher 2026 software multiple environment.

Valuation

$1.4B

ARR

$100M

TerraPower

TerraPower is one of the most credible US advanced-nuclear commercialization stories approaching market entry, but public-only evidence still cannot support a clean underwriting call because valuation, economics, and fuel-chain details remain opaque.

Moglix

Moglix is a scaled, improving B2B industrial-procurement platform at an inflection point, but the $2.5–2.6B last-round valuation remains stretched relative to public comparables; track pending profitability confirmation and IPO-readiness disclosure.

Valuation

$2.6B

Revenue run-rate

$595M

Growth

5.5%

Flash Express

Flash Express is a real Thai logistics scale winner with verified 2024 profitability, but thin margins, opaque private-market terms, and a stale 2022 valuation anchor justify a research-more stance rather than fresh underwriting at the last mark.

Valuation

$2.1B

Revenue run-rate

$670M

Growth

23.1%

Clip

Clip has real strategic value as a scaled Mexican SMB-payments platform, but limited audited disclosure and a demanding $2 billion price keep the call at RESEARCH-MORE with medium confidence and a stretched valuation stance.

Valuation

$2B

Revenue run-rate

$173M

At-Bay

At-Bay has built a credible InsurSec platform with meaningful SMB distribution, own-paper underwriting control, and an emerging security upsell engine, but public evidence still supports a research-more recommendation because underwriting, retention, and cap-table economics are not disclosed well enough to underwrite a clean entry near the estimated $2.1B mark.

Valuation

$2.1B

Growth

20.2%

Retool

Retool has credible product-market fit and strategic relevance in governed internal software, but the last disclosed $3.2B valuation still looks stretched against 2026 public comps and the company's thin public financial disclosure.

Valuation

$3.2B

ARR

$120M

Blink Health

Blink has real national prescription-access reach and fresh Series D support, but opaque economics, conflicting private-market marks, and elevated regulatory and operational risk keep the case at research-more with a stretched valuation stance.

Newcleo

Newcleo has stronger technical depth and regulatory traction than many European advanced-nuclear peers, but the public case still depends on repeated financing, future customer conversion, and milestone execution at a valuation that already prices in meaningful success.

Valuation

$2.4B

ID.me

ID.me is a real reusable-identity asset with national-scale reach, but the current >$2B private mark still runs ahead of the public evidence on revenue quality, margins, concentration, and policy durability.

Valuation

$2B

80 Acres Farms

80 Acres Farms appears to be the most credible remaining U.S. vertical-farming consolidator, but no audited financials and no disclosed valuation justify TRACK rather than BUY.

Growth

60%

Skyryse

Skyryse has built a differentiated software-defined flight-control platform with real certification progress and credible dual-use partner pull, but the $1.15B valuation already prices in substantial execution success before public revenue proof exists.

Valuation

$1.2B

Pomelo Care

Strong outcomes and category momentum make Pomelo worth tracking, but public evidence does not yet justify confident underwriting at a $1.7B valuation.

Valuation

$1.7B

BioCatch

BioCatch is a scaled, sponsor-backed fraud platform with credible bank traction and a more supportable valuation than in 2024, but public evidence still supports only a track posture until private economics, concentration, privacy controls, and deal terms are verified.

Valuation

$1.3B

ARR

$185M

Growth

43%

Mynt

Research more: Mynt / GCash is a systemically important Philippine fintech with real earnings contribution, dense customer reach, and broad product breadth, but the marketed IPO range is stretched until prospectus-grade disclosure closes the main financial, credit, and retention gaps.

Valuation

$5B

Thought Machine

Thought Machine has real product differentiation, credible customer proof, and strong modernization tailwinds, but the public record still does not justify underwriting the stale 2022 valuation without materially deeper financial diligence.

Valuation

$2.7B

ARR

$70.6M

Growth

-0.4%

Aragen Life Sciences

Aragen is a credible scaled Indian CRDMO with improving disclosure and customer depth, but the last-round ~$1.4 billion benchmark already prices in much of the visible upside while execution, compliance, and utilization evidence remains incomplete.

Valuation

$1.4B

Growth

11.3%

Pathos AI

Pathos AI has assembled a credible AI drug development platform with strong pharma partnerships and a multi-asset oncology pipeline, but clinical and regulatory derisking remains early-stage with material key-person and concentration risks

Valuation

$1.6B

Avride

Avride is strategically relevant and commercially live across robotaxis and delivery robots, but the active NHTSA probe, partner concentration, and sparse financial disclosure support only a cautious track posture and a discount to headline unicorn narratives.

Gamma

Gamma is the most capital-efficient path to $100M ARR in AI SaaS and warrants a conditional buy at a 15–20% discount to the Series B price, subject to private diligence confirming net dollar retention, gross margin, and enterprise revenue durability.

Valuation

$2.1B

Revenue run-rate

$100M

ARR

$102M

Growth

365%

osapiens

osapiens has enough growth, product breadth, and customer proof to justify continued diligence, but the public record still does not defend paying above a $1B valuation with conviction.

Valuation

$1.1B

Iterative Health

Iterative Health shows unusually strong public proof of network performance and strategic relevance, but the current unicorn valuation still requires revenue and margin evidence that has not been disclosed.

Valuation

$1.3B

Persona

Track Persona: it is a scaled, strategically relevant identity platform, but the $2B Series D valuation is stretched on public evidence until private ARR, retention, margin, concentration, legal-reserve, and cap-table diligence support it.

Valuation

$2B

Growth

100%

Unconventional AI

Unconventional AI is attacking a real and increasingly important AI power bottleneck with rare founder-market fit and exceptional access to capital, but public evidence still supports treating it as a thesis-driven research bet rather than an investable operating company at the current price.

Valuation

$4.5B

Lila Sciences

Lila is one of the best-capitalized AI-for-science startups in market, but the current valuation already assumes scientific and commercial proof that the public record has not yet fully shown.

Valuation

$1.3B

Distyl

Distyl has credible proof that it can move enterprise AI workflows into production, but the public record is still too thin on revenue quality and durability to justify underwriting the $1.8 billion valuation.

Valuation

$1.8B

Decagon

Decagon pairs real enterprise AI-CX traction and strong product depth with a valuation that has moved faster than the public denominator, leaving the current $4.5 billion mark hard to underwrite without private diligence.

Valuation

$4.5B

Revenue run-rate

$35M

Serval

Serval has exceptional investor conviction and a credible AI-native ITSM architecture, but the unanchored revenue growth claim, all-tech-startup customer base, sub-30-person headcount, and complete absence of disclosed unit economics leave the $1B valuation impossible to underwrite from public evidence alone.

Valuation

$1B

Chapter

Chapter appears to be a credible, fast-scaling Medicare-navigation company with partner-led distribution and strong public growth signals, but the current private price is hard to justify from disclosed evidence alone because valuation, retention, and capital-structure details remain opaque.

ARR

$100M

Growth

200%

Semperis

Semperis is the definitive identity-resilience platform for Active Directory and Entra ID, with $100M+ ARR, 1,000+ enterprise customers, and a durable AD-specific moat — but the $1B+ valuation at ~10x ARR is priced for continued high growth, and Microsoft bundling, opaque financials, and platform-consolidation pressure from CrowdStrike and SentinelOne make this a research-more rather than an outright buy at current price.

Valuation

$1B

ARR

$100M

Jumbotail

Jumbotail has built a strategically relevant B2B commerce and new-retail platform for kiranas and MSMEs, but public evidence still shows wholesale-heavy, loss-making economics and elevated integration or control risk, so the current unicorn pricing belongs on a watchlist rather than in the portfolio.

Valuation

$1B

Xcimer Energy

Xcimer pairs a differentiated laser-fusion architecture and strong early investors with real technical ambition, but no public valuation, no public customer proof, and very high technical and capital-intensity risk keep the name in research-more territory until milestone and commercial evidence materially improve.

ZaiNar

ZaiNar has a plausible network-positioning wedge and unusual patent depth, but absent named partners, clean backlog quality, and disclosed unit economics, the current public record supports tracking rather than underwriting the $1B-plus mark.

Valuation

$1B

Parloa

Parloa's 150% NRR, 117% ARR growth, and blue-chip enterprise proof justify a premium, but the January 2026 Series D prices the company at ~58x ARR—a stretched multiple that leaves limited cushion for execution misses. Prudent stance is Research More until gross margin, GRR, and forward-growth evidence catch up to the $3B mark.

Valuation

$3B

ARR

$52M

Growth

117%

NRR

150%

Liftoff Mobile

Liftoff Mobile holds a durable dual-sided marketplace position in mobile advertising, but AppLovin's data advantages and privacy headwinds create structural competitive pressure.

Valuation

$4.3B

Stoke Space

Stoke Space's reusable upper-stage thesis is a real differentiator and its financing base is unusually strong, but a ~$3.42B secondary valuation already prices in significant execution before orbital proof, named customer conversion, or revenue disclosure are public.

Valuation

$3.4B

Nominal

Nominal's 7x revenue growth and four-of-five-largest-defense-contractor deployment prove real product-market fit in a structurally underserved niche, but undisclosed absolute revenue and gross margin prevent a buy call at a $1 billion valuation that requires roughly $60–90 million of ARR to be supportable.

Valuation

$1B

Growth

700%

TRM Labs

TRM Labs' 150%+ annual growth and rare dual presence in both private-sector compliance and government investigations makes it one of the most defensible blockchain intelligence platforms, but Chainalysis's entrenched position and market cyclicality warrant careful sizing.

Valuation

$1B

Growth

150%

Wave Mobile Money

Track: Wave combines rare mobile-money scale and strong price-led adoption with limited financial disclosure, meaningful regulatory complexity, and stale public equity price discovery.

Valuation

$1.7B

Pudu Robotics

Pudu Robotics combines real global deployment scale and strong category breadth with improving capital access, but public evidence still leaves too much uncertainty on revenue quality, margins, concentration, and round terms to underwrite the April 2026 unicorn valuation aggressively.

Valuation

$1.5B

Growth

100%

Razorpay

Razorpay looks like one of India's strongest private merchant-fintech assets, but the public record still supports tracking and further diligence rather than paying the highest private valuation headlines with conviction.

Valuation

$9.2B

Growth

65%

Pacific Fusion

Pacific Fusion combines elite scientific talent, unusually transparent technical evidence, and extraordinary early capital, but the public record still lacks the price, structure, and customer proof needed for a responsible underwriting call. Recommendation: research-more until term-sheet, full-module, and counterparties evidence closes the gap.

Bolttech

Bolttech has credible global embedded-insurance scale and strategic momentum, but public disclosure is still too thin to underwrite the June 2025 unicorn valuation with conviction.

Valuation

$2.1B

Poolside

Poolside has a credible sovereign-enterprise product thesis and meaningful upside if secure coding AI becomes a durable high-ACV category, but public evidence is still too thin on revenue quality, customer proof, and infrastructure execution to support an aggressive buy recommendation.

Valuation

$3B

MiniMax

MiniMax has built one of the broader product surfaces among private AI companies and appears commercially real at meaningful scale, but live IP litigation, governance and financial opacity, and intense pricing competition keep the story in Track rather than buy territory at reported late-stage marks.

Valuation

$4B

ARR

$150M

Growth

158.9%

Exabeam

Exabeam is the strongest independent SIEM/UEBA challenger thanks to its AI-native Nova platform, but near-term value depends on executing the LogRhythm integration without material customer attrition.

Valuation

$2.4B

Sierra AI

Sierra combines elite founders, exceptional early enterprise traction, and deep capital access, but the May 2026 $15.8 billion valuation leaves little margin for error without deeper diligence.

Valuation

$15.8B

ARR

$150M

Tomorrow.io

Tomorrow.io has a technically differentiated satellite moat validated by NOAA and institutional investors at unicorn scale, but an unresolved 4× ARR discrepancy, undisclosed gross margin, and capital-intensive DeepSky program make commitment at $1B unjustifiable without data-room confirmation.

Valuation

$1B

Revel

Revel has a credible control-software wedge and unusually strong founder-market fit, but public metrics remain too thin to justify conviction at the third-party-reported $1B+ valuation.

Valuation

$1B

Halter

Halter has built a credible category-leading livestock operating platform with real customer and product-scale proof, but public evidence still supports only a research-more posture at the $2B mark until private unit economics, governance, and welfare durability are underwritten.

Valuation

$2B

Trendyol

Trendyol is the dominant Turkish e-commerce platform with decacorn GMV scale and domestic profitability, but its $16.5B last mark is five years stale, implying a 6.6–9.2x EV/Revenue premium to emerging-market peers, making it unattractive at the 2021 price with no confirmed exit mechanism.

Valuation

$16.5B

Revenue run-rate

$2B

Growth

32%

Bugcrowd

Bugcrowd is a genuine crowdsourced cybersecurity market leader—FedRAMP Moderate authorized, 1,200+ enterprise customers, 40%+ reported revenue growth, and a differentiated AI+human platform post-Mayhem acquisition—but the informal ~$2B valuation mark is stretched versus a base-case analysis of $1.2B–$1.7B, six critical diligence items remain unresolved, and financial opacity (no audited revenue, NRR, or gross margin disclosure) limits conviction; Track / Research-More pending data-room access.

Valuation

$2B

Growth

40%

True Anomaly

True Anomaly is strategically relevant and increasingly well-capitalized, but the public record still supports a cautious, high-risk, price-sensitive stance because mission proof outpaces economic disclosure.

Valuation

$2.2B

Midi Health

Midi has built a scaled, insurer-friendly menopause telehealth platform, but the current unicorn valuation outstrips what public evidence alone can underwrite.

Valuation

$1B

Revenue run-rate

$150M

Growth

150%

Grow Therapy

Scaled payer-connected mental-health platform with real network breadth, but the investment case still hinges on proving revenue quality and managing reimbursement-heavy execution risk.

Valuation

$3B

Revenue run-rate

$1B

Whop

Whop has real creator-commerce scale and increasingly differentiated payments rails, but the February 2026 $1.6B mark already prices in premium execution despite limited audited disclosure and live trust, moderation, and dispute-handling risk.

Valuation

$1.6B

Revenue run-rate

$142M

Growth

74%

Nyobolt

Research-more: Nyobolt has credible product proof, strategic validation from Symbotic, and clear commercial momentum, but the May 2026 $1B valuation still looks stretched until diligence closes the revenue, margin, concentration, and preference-term gaps.

Valuation

$1B

Growth

400%

Replit

Replit has real category-leading adoption and enterprise momentum, but the current $9B mark still outruns the quality of public financial disclosure.

Valuation

$9B

Udaan

Track: Udaan's turnaround is credible enough to defend a scenario-based $1.4-1.9B base case, but the current $1.8B mark is not a wide-margin-of-safety entry while revenue quality remains inventory-led and key runway, credit, and dilution inputs are still undisclosed.

Valuation

$1.8B

Revenue run-rate

$540M

Growth

-20.1%

Ualá

Ualá has real regional scale, product breadth, and continuing sponsor support, but limited consolidated disclosure and Mexico credit risk keep the case at TRACK with high residual risk and a fair, price-sensitive current valuation.

Valuation

$3.2B

Cohere Health

Real payer-workflow scale, but undisclosed price and economics keep Cohere in research-more territory.

Darktrace

Darktrace still looks like a scaled, strategically relevant cyber platform, but sponsor-era opacity on debt, governance, and current operating performance keeps the name in track rather than buy territory.

Valuation

$5.3B

ARR

$782.2M

NRR

106.6%

StackAdapt

StackAdapt looks like a real, scaled, and likely profitable adtech winner, but the secondary-heavy 2025 round, premium reported valuation, and incomplete financial disclosure keep the current underwriting case in the track-not-buy bucket.

Valuation

$2.5B

Revenue run-rate

$500M

Baseten

Baseten is a high-quality AI inference infrastructure company with real enterprise traction and strong category positioning, but public financial disclosure is too thin to justify treating momentum pricing as a high-conviction buy.

Valuation

$5B

Revenue run-rate

$600M

Growth

1,900%

Awardco

Awardco appears to be a high-quality, capital-efficient HR-tech platform with a real product moat and meaningful scale, but the current >$1B valuation already assumes continued 30%+ growth that public data cannot fully verify.

Valuation

$1B

Revenue run-rate

$106.6M

ARR

$75.2M

Growth

73%

Polymarket

Polymarket is the dominant global prediction-market platform with credible institutional and regulatory progress, but governance concentration, market-integrity questions, and a valuation far ahead of disclosed fundamentals keep it in track territory.

Valuation

$9B

Revenue run-rate

$300M

Filevine

Credible legal-workflow leader, but the current ~$3B mark is ahead of public proof on margins, investor terms, and realized AI economics.

Valuation

$3B

Revenue run-rate

$205M

ARR

$205M

Growth

58%

NRR

120%

Gradiant

Gradiant appears to be a real and strategically relevant premium industrial-water company with differentiated technology and strong market tailwinds, but the current $2B headline valuation already prices in much of the upside before investors receive audited financial disclosure.

Valuation

$2B

Growth

50%

SandboxAQ

SandboxAQ is a technically credible Alphabet spinout with real government traction and elite investor backing, but a $5.75 B valuation at ~315× unverified ARR demands revenue confirmation before a buy case can be supported.

Valuation

$5.8B

Talkiatry

Talkiatry is the category-leading in-network telepsychiatry provider group with 800+ employed psychiatrists, broad payer coverage, and validated outcomes, but a labor-intensive W-2 model, fully undisclosed unit economics, prescribing-regulatory exposure, and an unconfirmed ~$1.4B inferred mark make it a track / research-more rather than an underwrite-now opportunity.

Revenue run-rate

$95M

Galaxea AI

Galaxea AI has best-in-class academic credentials, a credible product roadmap, and genuine developer traction, but zero verified commercial revenue, a stretched ~$2.9B valuation implying >290x on 2025 guidance, and high geopolitical and disclosure risk that make it uninvestable without further transparency.

Valuation

$2.9B

Meter

Meter has a credible full-stack networking product and real customer proof, but the current ~$1B mark is hard to underwrite without revenue, margin, and concentration data.

Valuation

$1B

Also

Also has authentic Rivian engineering DNA, a differentiated DreamRide propulsion system, and a DoorDash commercial anchor—but it is a pre-revenue hardware startup valued at $1 billion before mass production, with unresolved delivery timelines, battery-safety regulatory exposure, and capital requirements that make the current benchmark high-risk for new investors.

Valuation

$1B

Proof

Proof has built the leading RON and identity-authorization platform with 7,000+ customers and real transaction scale ($200B+ annually), but the investment case is complicated by financial opacity, housing-cycle concentration, a 2022 restructuring, and a Forge secondary mark (~$987M) that implies double-digit revenue multiples versus public comps—without disclosed ARR, margin, or NRR evidence to validate the premium.

Valuation

$987M

Kikoff

Kikoff has real customer reach and a differentiated low-friction credit-building bundle, but the public record still leaves too much uncertainty around retention, complaint quality, and revenue to underwrite the reported unicorn valuation with conviction.

Valuation

$1B

EliseAI

EliseAI has crossed $100M ARR with dominant multifamily penetration and tier-1 backing, but a 22x ARR multiple and unresolved fair-housing regulatory exposure make the current price stretched for investors without regulatory diligence access.

Valuation

$2.2B

ARR

$100M

CompanyCam

CompanyCam has built a defensible contractor documentation moat with 285,000+ users, proven 2x ARR growth to $68M in 2024, and Nebraska's first unicorn valuation—but a ~29x 2024 ARR multiple demands ongoing acceleration that public evidence cannot yet confirm, warranting a track posture pending current ARR disclosure.

Valuation

$2B

ARR

$68M

Growth

113%

HawkEye 360

HawkEye 360 looks strategically real—differentiated RF GEOINT capability, meaningful government traction, backlog, and new public-market liquidity are all visible—but concentrated public-sector exposure, backlog-quality caveats, capital intensity, and still-opaque recurring economics justify a track stance rather than a buy call at the current public valuation.

Valuation

$3B

Growth

74%

Divergent Technologies

Divergent has credible technical edge and defense-aligned market timing, but private-market pricing and sparse financial disclosure argue for a track stance rather than immediate conviction buying.

Curative

Curative has a credible employer-plan wedge, real 2025 financing validation, and enough public member scale to stay on the watchlist, but the current $1.275 billion mark still looks stretched because audited underwriting, reserve, and renewal data remain private.

Valuation

$1.3B

Castelion

Castelion combines rare DoD demand pull, credible founder-market fit, and a manufacturing-first thesis that could matter if the Pentagon truly shifts hypersonics from boutique programs to mass procurement, but the current ~$2.8B valuation already prices in substantial execution and production success.

Valuation

$2.8B

Flock Safety

Flock Safety is a real, scaled public-safety platform, but the 2025 round already prices in a favorable margin-and-trust outcome that the public record does not yet prove, so the right call remains TRACK rather than buy.

Valuation

$7.5B

ARR

$300M

Growth

70%

EnerVenue

EnerVenue has genuine chemistry differentiation and strong strategic financing, but revenue opacity and China-centered manufacturing keep the investment case in research-more territory.

Fuse Energy

Fuse Energy is a founder-led, vertically integrated UK energy challenger with credible traction and product breadth, but the reported $5 billion valuation is hard to underwrite from public evidence because ARR quality, margins, liquidity, and private-round terms remain opaque.

Valuation

$5B

ARR

$400M

Zama

Zama looks like the clearest public leader in FHE-based confidential blockchain infrastructure, but the current valuation sits ahead of disclosed commercialization proof, supporting a research-more stance rather than a buy call.

TAE Technologies

TAE has one of the stronger publicly visible private-fusion science programs, but today's entry price is unsupported by disclosed plant economics, customer proof, or the pending merger's full disclosure pack.

Valuation

$2.9B

SumUp

SumUp is a scaled and strategically relevant SMB-payments platform, but the public record still supports only a track call because economics, capital structure, and governance disclosure lag the valuation narrative.

Valuation

$8.5B

Growth

30%

Sierra Space

Sierra Space is a well-capitalized but still under-disclosed space-and-defense platform whose $8 billion March 2026 valuation looks stretched until Dream Chaser converts its late-2026 demo into contracted demand and management opens the revenue, margin, and term-sheet denominator.

Valuation

$8B

Zip

Zip has credible product-market proof, category leadership signals, and large-enterprise customer traction, but the current $2.2B reference valuation is stretched against publicly unverifiable revenue quality and still-opaque financing terms.

Valuation

$2.2B

OneTrust

OneTrust is the category-defining privacy-to-AI governance platform at a $4.5B last mark, but new capital is not actionable without confirmed NRR, EBITDA margins, and PE acquisition structure.

Valuation

$4.5B

Game Science

Game Science proved with Black Myth: Wukong that a founder-led Chinese studio can ship a world-class premium hit, but single-franchise concentration, limited financial disclosure, and unclear sequel economics keep the investable posture at research-more rather than buy.

Airalo

Airalo is a real, scaled leader in travel eSIMs with broad consumer and channel reach, but public evidence remains too thin on current revenue quality, margins, and downside terms to justify more than a track posture at the 2025 unicorn valuation.

Valuation

$1B

Statsig

Statsig built a credible integrated experimentation platform, but the announced OpenAI deal and still-private economics make it an avoid for fresh capital.

Valuation

$1.1B

ARR

$40M

Wireless Logic

Wireless Logic appears to be a scaled, profitable, strategically credible IoT connectivity platform, but the current private-market price still outruns the public evidence base.

Valuation

$4.7B

Growth

20%

Peregrine Technologies

Peregrine has exceptional growth credentials and Tier-1 investor validation but is priced at ~61x ARR — more than twice the concurrent Flock Safety comp — in a market with escalating civil-liberties risk and entirely undisclosed unit economics; conditional track pending ARR audit, NRR confirmation, and valuation step-down.

Valuation

$2.5B

ARR

$40.9M

Dataminr

Dataminr is a real, scaled, differentiated intelligence platform, but the unchanged 2021 valuation headline looks hard to underwrite after 2025 bridge-like convertibles and persistent disclosure gaps.

Valuation

$4.1B

Revenue run-rate

$200M

ARR

$200M

SambaNova Systems

SambaNova has credible technical differentiation and sovereign/government traction, but opaque economics, customer concentration, and valuation ambiguity keep the equity story in research-more territory.

Valuation

$2.3B

Revenue run-rate

$180M

ARR

$180M

Growth

80%

Enpal

Enpal combines category-leading scale in German residential solar with a broadened home-electrification bundle and unusually deep structured-finance access, but opaque post-2023 valuation, limited audited profitability disclosure, service-quality/legal friction, and policy sensitivity justify a Track rating rather than an invest-now recommendation.

Valuation

$2.4B

Revenue run-rate

$1.2B

Growth

25%

ClickHouse

ClickHouse has strong product-market pull, credible cloud monetization, and marquee customer adoption, but its private-market valuation already prices in substantial future execution despite limited public disclosure on revenue quality and margins.

Valuation

$6.4B

Revenue run-rate

$160M

ARR

$160M

Growth

256%

VAST Data

VAST Data looks like a genuine AI infrastructure winner with real scale, strong ecosystem proof, and differentiated data-platform technology, but the current $30 billion valuation still requires private diligence on revenue quality, concentration, and cap-table terms before new money can be underwritten confidently.

Valuation

$30B

ARR

$500M

Moon Active

Moon Active combines rare mobile-gaming scale with likely cash generation, but Coin Master concentration and private-company opacity keep the investment case in track rather than buy territory.

Valuation

$9B

Revenue run-rate

$2B

Job&Talent

Job&Talent shows real operating scale, improving profitability, and credible AI workflow traction, but the 2025 down round and opaque capital structure leave the current entry price too demanding for a higher-conviction underwriting call.

Valuation

$1.5B

Cera

Cera has real AI-enabled home-care scale and credible public-sector demand, but debt-heavy financing and incomplete disclosure support a watch posture rather than an aggressive entry.

Valuation

$1B

Revenue run-rate

$500M

BigID

BigID looks like a real, strategically relevant late-stage data-security platform, but public evidence is still too opaque to underwrite aggressively above a disciplined secondary-entry price.

Valuation

$531.5M

Revenue run-rate

$139.5M

ARR

$100M

Growth

32.7%

Ambience Healthcare

Ambience Healthcare leads the ambient AI scribe category but trades at a steep 42x estimated ARR multiple that leaves little margin for execution risk.

Valuation

$1.3B

ARR

$30M

Electric Hydrogen

Electric Hydrogen has one of the strongest Western large-plant electrolyzer platforms, but its stale unicorn valuation still outruns proof of commercial conversion in a deteriorated green-hydrogen market.

Valuation

$1B

Aiven

Aiven has credible product breadth, enterprise customer proof, and multi-cloud differentiation, but the stale $3B 2022 mark is not investable in 2026 given opaque financials, heavy competitive pressure, and uncertain capital adequacy.

Valuation

$3B

Revenue run-rate

$109M

ARR

$109M

Hai Robotics

Hai Robotics is a real category leader in ACR-based warehouse automation, but the public record still supports tracking rather than buying because pricing, dilution, and recurring-economics disclosure remain incomplete while losses and concentration stay material.

Valuation

$1.5B

Revenue run-rate

$190M

Growth

68.6%

Veho

Veho is a high-growth last-mile delivery operator with genuine brand differentiation and strong customer outcomes, but existential IC reclassification risk, a four-year-stale $1.5B valuation mark, and complete financial opacity cap conviction at "track" pending audited financials and a capital raise event.

Valuation

$1.5B

Growth

90%

Bitdefender

Bitdefender is a real, profitable hybrid cybersecurity franchise with credible endpoint/XDR technology and global distribution, but private-company disclosure gaps, a consumer-heavy mix, and preference-stack opacity keep the case at research-more rather than buy ahead of any IPO.

Valuation

$2.2B

Revenue run-rate

$435M

Growth

11%

IQM Quantum Computers

IQM is one of Europe's strongest quantum hardware assets, but the current de-SPAC entry still depends on unaudited revenue, a binary transaction close, and proof that sovereign-heavy deployments can compound into durable commercial economics.

Valuation

$1.8B

ICEYE

ICEYE is one of the strongest private space companies on public evidence, but the current price already assumes sovereign-contract execution and margin durability that outside investors still cannot fully verify.

Valuation

$2.8B

d-Matrix

d-Matrix has a differentiated inference architecture and credible commercialization momentum, but the $2B Series C still gets ahead of public proof on revenue, customer depth, and durable deployment economics.

Valuation

$2B

Isar Aerospace

Isar Aerospace combines unusual strategic relevance, capital access, and real launch progress for a European private launcher, but without orbital success, clean commercial disclosure, or transparent convert terms, it remains a research-more story rather than an underwritable buy.

Redpanda

Redpanda combines strong Kafka-compatible technology, blue-chip production references, and real market tailwinds, but the April 2025 $1B Series D price remains difficult to justify without disclosed unit economics or independently corroborated scale metrics.

Valuation

$1B

ARR

$26.1M

Growth

300%

Zum

Zum has built real late-stage scale in student transportation, but incomplete disclosure on margins, concentration, and EV project economics keeps the stock-story equivalent at research-more rather than buy.

Valuation

$1.7B

Growth

35%

MNT-Halan

MNT-Halan has built genuine late-stage fintech scale, but incomplete disclosure on credit quality, margins, and capital structure keeps the investment case in research-more territory.

Valuation

$1B

Flex

Flex appears to have built a genuine distribution moat in rent-payment flexibility, but undisclosed capital structure, opaque credit economics, and a meaningful record of servicing failures keep the correct call at research-more rather than a price-sensitive underwriting.

Revenue run-rate

$141.8M

Creatio

Creatio looks like a credible late-stage workflow-automation platform, but missing public denominator data keeps the 2024 $1.2B mark in stretched territory and the recommendation at research-more.

Valuation

$1.2B

Aven

Aven has created a genuinely differentiated fintech product—the home-equity-backed credit card—with strong early traction, but execution risk around the CCB bank dependency, FCRA litigation, and the untested 'machine banking' roadmap warrants a careful track rating ahead of any Series F or IPO.

Valuation

$2.2B

Revenue run-rate

$200M

ARR

$200M

Mech-Mind Robotics

Mech-Mind has real industrial-AI deployment depth and credible technical integration, but public disclosure still supports only a research-more stance at unicorn pricing.

Quantinuum

Quantinuum is one of the strongest pre-IPO quantum platforms, but a $10B valuation on only $30.9M of 2025 revenue, a $192.6M net loss, and unresolved Honeywell control terms keeps the name in track territory rather than buy territory.

Valuation

$10B

Growth

34.3%

Handshake

Handshake looks like a real category leader in early-career recruiting with meaningful platform optionality, but the public evidence is still insufficient to underwrite the stale 2022 unicorn price with confidence.

Valuation

$3.5B

ARR

$172M

Growth

28.8%

Marshmallow

Marshmallow has a real and differentiated UK-newcomer insurance franchise with credible scale and a 2024 profitability inflection, but the >$2B 2025 mark still outruns the public disclosure needed for a buy call.

Valuation

$2B

Revenue run-rate

$500M

Growth

62%

Druva

Druva is a real, scaled cloud-data-protection platform with confirmed historical unicorn status, but stale valuation anchors, thin 2026 disclosure, and AWS/secondary-market concentration keep it in track territory.

Valuation

$772.7M

Revenue run-rate

$304.3M

ARR

$200M

Oishii

Oishii looks like one of the more credible survivors in indoor farming, but the public case still leans on brand and capital more than fully disclosed economics.

Thyme Care

Thyme Care looks like a credible scaled oncology-navigation platform with real payer/provider traction, but public financial opacity and a likely stretched late-stage mark keep the current call at track rather than buy.

Valuation

$1.5B

Base Power

Base Power has a differentiated residential-battery plus retail-power model and real early Texas traction, but the latest $4B mark already prices in durable ERCOT economics and successful multi-state replication that public evidence does not yet prove.

Valuation

$4B

Pathos

Pathos AI has assembled a credible AI drug development platform with strong pharma partnerships and a multi-asset oncology pipeline, but clinical and regulatory derisking remains early-stage with material key-person and concentration risks

Valuation

$1.6B

Enveda Biosciences

Enveda's Phase 1b ENV-294 data and $517M capital base establish real clinical credibility, but a binary Phase 2a readout, undisclosed financials, and an unconfirmed unicorn valuation keep it in watch-and-track territory.

Ayar Labs

Ayar Labs is the best-funded pure-play in-package optical I/O company, with a blue-chip strategic cap table, a working TeraPHY+SuperNova stack, and a credible 2026-2027 ramp window — but commercial revenue is unproven, NVIDIA and Broadcom's in-house CPO programs raise real competitive risk, and the exact Series D valuation premium versus Lightmatter and Celestial AI is hard to justify without revenue visibility. Track closely; not yet de-risked enough to underwrite aggressively.

Valuation

$1B

Function Health

Function Health has executed a textbook celebrity-physician DTC launch into the preventive-health market — roughly one million members and a self-reported $100M ARR in under three years, anchored by Mark Hyman's brand and Quest Diagnostics' nationwide lab footprint. The $298M Series B at $2.5B (~25x ARR) is stretched against public DTC-health comparables, the effective $100 ARPU is unreconciled against the $499 list price, and adverse press from the NYT Well desk, TIME, and independent scientific critics raises overdiagnosis, FTC endorsement, and laboratory- developed-test (LDT) regulatory questions. Track until unit economics, retention, and clinical/regulatory posture clarify.

Valuation

$2.5B

Revenue run-rate

$100M

ARR

$100M

Sila Nanotechnologies

Sila has real product and factory proof, but the absence of disclosed revenue, margin, and a confirmed valuation keeps it a price-sensitive track rather than an actionable buy.

Acronis

Acronis is a credible channel-anchored cyber-protection platform with a fresh EQT capital event at an implied $3.5B EV, but no audited financials and a first-ever FASCSA federal exclusion order make this a research-more, not a conviction, story for 2026 underwriting.

Valuation

$3.5B

Revenue run-rate

$426M

ARR

$426M

Creditas

Creditas is a scaled Brazilian secured-credit platform with improving margins and strategic funding optionality, but it remains too opaque and rate-sensitive for high-conviction underwriting at the latest mark.

Valuation

$3.3B

Growth

23.1%

Supabase

Supabase has real platform traction and product depth, but limited public disclosure tempers conviction at a $2B valuation.

Valuation

$2B

OpenEvidence

OpenEvidence has built unusually strong clinician adoption and a genuine premium-content moat, but the January 2026 $12 billion valuation runs far ahead of public evidence on revenue quality, advertiser durability, enterprise depth, and governance disclosure.

Valuation

$12B

Revenue run-rate

$150M

Flatpay

Flatpay has rare SMB-merchant growth and a compelling simplicity pitch, but the public record still does not prove durable unit economics or enough disclosure to underwrite a €1.5B entry with high confidence.

Valuation

$1.8B

ARR

$110M

n8n

n8n is one of the fastest-growing enterprise automation platforms in Europe, with compelling community moat, strong AI-native positioning, and institutional validation—but stretched Series C valuation and absent unit economics warrant a disciplined track rather than immediate buy.

Valuation

$2.5B

ARR

$40M

Strava

Strava is a scaled, premium-capable social fitness network, but the latest private-market mark still looks rich relative to what public evidence proves.

Valuation

$2.2B

ARR

$500M

Growth

18.5%

Ninja Van

Ninja Van has real regional logistics scale and credible adjacencies in B2B restocking and cold chain, but weak public financial disclosure and a 2025 valuation reset leave the current underwriting case incomplete.

Valuation

$1B

Group14 Technologies

Group14 is one of the most credible private battery-materials platforms in advanced anodes: it has real commercial deployments, a blue-chip strategic cap table, and a now-operating Korean production asset. But the underwriting case is constrained by BAM-2 execution slippage, policy and supply-chain dependencies, and sparse financial disclosure. On today's estimated valuation, the name looks interesting enough to track closely, but not yet de-risked enough to underwrite aggressively.

Valuation

$5.3B

Revenue run-rate

$39M

Aura

Aura has enough scale, product breadth, and partner distribution to merit continued diligence, but the combination of private-company opacity and trust overhang keeps the recommendation at research-more rather than buy.

Valuation

$1.6B

Growth

50%

Apex

Apex has credible product, factory, and government-demand proof, but the public record still lacks backlog conversion, unit economics, and financing details; at the last disclosed >$1B mark, the right call is research-more with a stretched valuation stance.

Valuation

$1B

Substack

Substack has genuine creator-platform scale and differentiated network effects, but the 2025 unicorn valuation looks expensive against estimated ARR, visible creator churn pressure, and elevated legal-platform risk.

Valuation

$1.1B

Revenue run-rate

$45M

ARR

$45M

Growth

22%

MoEngage

MoEngage looks like a real, scaled engagement platform, but public disclosure is too thin and the late-2025 pricing too rich to support a buy call from public evidence alone.

Kalshi

Kalshi's CFTC regulatory moat and explosive revenue trajectory are real, but the $22B Series F price embeds a favorable legal outcome for sports event contracts that is not yet in evidence, making the valuation stretched and the appropriate posture research-more until key litigation catalysts resolve.

Valuation

$22B

Revenue run-rate

$1.5B

PostHog

PostHog looks like a real multi-product developer platform, but public evidence still does not justify paying the reported $1.4B price with discipline.

Valuation

$1.4B

MaintainX

MaintainX is a strong vertical SaaS operator in industrial maintenance, but the $2.5B Series D mark looks stretched without audited revenue, NRR, or margin disclosure.

Valuation

$2.5B

Teamworks

Teamworks looks like the leading vertical software platform for elite sports — with unusually deep league penetration, a broad workflow suite, and strong AI-oriented acquisitions — but the current $1B+ valuation sits on top of a public record that is far richer on scale and fundraising than on revenue quality, margin structure, or integration economics.

Valuation

$1B

Nourish

Nourish has built a scaled, payer-aligned virtual metabolic-care platform with strong clinical and distribution signals, but the reported $1.75 billion 2026 valuation looks stretched until management discloses revenue, margins, and reimbursement durability in more detail.

Valuation

$1.8B

Clio

Clio is a scaled, profitable legal-workflow leader with genuine product breadth and customer reach, but the current US$5 billion valuation (about 10x ARR) and persistent disclosure gaps support only a track stance.

Valuation

$5B

ARR

$500M

Armada

Armada has a credible sovereign-edge infrastructure wedge and unusually strong early deployment proof, but opaque economics, factory-scale execution risk, and a stretched 2026 price keep the company in research-more territory.

Valuation

$2B

Tenex

Tenex is a credible AI-native MDR operator with exceptional fundraising momentum and real early customer proof, but the public file is still too thin and too self-reported to justify conviction at a reported valuation above $1B.

XBOW

XBOW has unusually strong technical and ecosystem proof for a two-year-old cybersecurity startup, but the current valuation still outruns the public financial evidence.

Valuation

$1B

Gopuff

Track: Gopuff has genuine category leadership as the last scaled vertically integrated quick-commerce platform in the US and UK, but today's $8.5B private mark already prices in much of the operational recovery while audited financials, free-cash-flow timing, and capital-structure overhang remain opaque.

Valuation

$8.5B

Bedrock Robotics

Bedrock Robotics has credible early field proof and a strong autonomy pedigree, but its valuation already prices in execution that public economics and retention data do not yet verify.

Valuation

$1.8B

Verkor

Verkor is one of the more credible remaining European battery platforms because it has a live Dunkirk asset, Renault-backed demand, and €3B+ of committed capital, but the equity case is still too opaque and execution-sensitive for a buy call after Northvolt showed how fast battery-scale optimism can unwind.

FieldAI

FieldAI combines elite field-robotics talent, strong investor validation, and a differentiated hardware-agnostic embodied AI stack, but the lack of audited financial disclosure and limited named customer proof make the $2B valuation difficult to underwrite from public evidence alone.

Valuation

$2B

Tekever

Tekever is a rare battle-proven European UAS unicorn with credible sovereign demand anchors, but the £1B+ entry price is stretched against unaudited revenue and an undrawn OVERMATCH framework — track until data-room access confirms the financial thesis.

Valuation

$1.3B

Socket

Socket has real product-market fit in software supply chain security — strong AI/developer customer proof, transparent seat pricing, and a differentiated behavior-plus-reachability stack — but the May 2026 $1 billion Series C still looks slightly stretched on public evidence because ARR, retention, margins, burn, and cap-table terms remain undisclosed.

Valuation

$1B

Go1

Go1 appears to be a scaled and strategically relevant enterprise learning platform, but the public evidence supports the business more cleanly than it supports the latest private valuation.

Valuation

$2.8B

ARR

$94.8M

Growth

37.6%

Bitsight

Bitsight is a category-defining cyber risk intelligence platform with real scale, strategic relevance, and a plausible valuation anchor around the last public $2.4B mark, but the lack of audited economics, current financing terms, and clear preference-waterfall disclosure supports a research-more recommendation rather than a clean buy call.

Valuation

$2.4B

Revenue run-rate

$200M

ARR

$200M

WorkOS

WorkOS is a high-quality developer-first enterprise identity platform with unusually strong AI-customer proof, but the $2B March 2026 round still outpaces the public operating disclosure needed for a conviction buy call.

Valuation

$2B

Wellhub

Wellhub is the global leader in employer-sponsored wellness benefits with $319M ARR and genuine platform scale, but its $4.2B secondary-market valuation implies a 13.2x EV/ARR multiple on undisclosed financials — stretched versus all public and private comps — warranting a Track stance until gross margin, NRR, and post-USC integration economics are confirmed.

Valuation

$4.2B

Revenue run-rate

$319M

ARR

$319M

Hunters

Hunters appears to be a credible next-gen SOC platform with real enterprise logos and a differentiated vendor-agnostic architecture, but the absence of current financial disclosure and price discovery keeps the name in research-more territory rather than an investable buy.

Shadowfax

Shadowfax is a scaled and now-profitable Indian logistics platform, but current public-market pricing and customer-concentration risk justify a TRACK stance rather than aggressive upside underwriting.

Valuation

$1.4B

Growth

27%

Melio

Melio is a strategically valuable but still hard-to-underwrite SMB payments platform: Xero's deal confirms real scale and distribution value, yet the standalone economics remain too opaque to treat the strategic acquisition price as a reusable entry mark.

Valuation

$2.5B

Revenue run-rate

$187M

Alan

Alan has built the strongest full-stack digital health-insurance franchise in France, but unresolved underwriting opacity, cyber dependency, and public-sector concentration keep the current €5B valuation in watchlist rather than buy territory.

Valuation

$5.4B

Revenue run-rate

$868M

ARR

$868M

Growth

53%

Sunfire

Sunfire is a strategically relevant European electrolyzer scale-up with real industrial proof, but public-only evidence supports a research-more stance because economics, disclosure, and subsidy-linked project conversion remain too opaque to justify a full-price buy.

Valuation

$1.1B

J&T Express

J&T Express is a scaled, profitable HKEX-listed express operator trading below prior private and IPO-era reference points; Buy for valuation, but only with medium confidence because China pricing, platform concentration, and governance risk keep the risk rating high.

Valuation

$9.8B

Revenue run-rate

$12.2B

Growth

18.5%

Securiti AI

Securiti AI achieved a strong strategic exit at $1.725B — validating its unified data platform thesis — but revenue opacity and post-acquisition integration execution remain the key unresolved questions.

Valuation

$1.7B

Carro

Carro is a scaled Southeast Asian automotive platform with visible profitability progress and credible IPO optionality, but opaque capital structure, missing customer / unit-economics disclosure, and rumor-heavy valuation talk keep the risk-reward in TRACK territory around the US$3.0 billion anchor.

Valuation

$3B

Growth

15%

Chime

Chime looks like a scaled public consumer-fintech winner, but the current discount mostly reflects real sponsor-bank, regulatory, and disclosure risks rather than market misunderstanding alone.

Valuation

$6.8B

Revenue run-rate

$2.6B

Growth

25%

Strive Health

Strive has real kidney-care scale, channel breadth, and product relevance, but the public record still cannot bridge its September 2025 ~$1.8 billion mark to disclosed revenue, margin, renewal, and post-reset economics, so the right public-only posture remains research-more.

Valuation

$1.8B

SendCutSend

SendCutSend looks like a high-quality software-enabled manufacturing platform, but the May 2026 unicorn valuation already prices in a large share of the execution story while audited financials, debt terms, and preference-stack details remain private.

Valuation

$1B

Revenue run-rate

$200M

Growth

80%

Eight Sleep

Eight Sleep has credible product differentiation and a fresh $1.5B financing anchor, but opaque financials, trust-sensitive product risks, and a premium valuation keep the stockless underwriting case in track-not-buy territory.

Valuation

$1.5B

24M Technologies

Promising process IP never matured into a diversified base of gigawatt customers before partner concentration, capital intensity, and a battery-market downturn pushed 24M into liquidation.

Valuation

$1.3B

BillionToOne

BillionToOne merits a TRACK rating: the platform, growth, and liquidity are strong, but at roughly $3.95 billion and about 8.5x-8.8x 2026 revenue the shares look fairly valued versus unresolved reimbursement, litigation, and control risk.

Valuation

$4B

Revenue run-rate

$433.6M

Growth

84%

Plata

Banco Plata's extraordinary growth — 3.4 million customers and USD 596 million annualized revenue in under three years — validates its model, but a 23.9% cost of risk, pre-profitability, concentrated wholesale funding, and a USD 3.1 billion valuation that demands sustained execution justify a TRACK stance until a clearer path to profitability and deposit funding is visible.

Valuation

$3.1B

Revenue run-rate

$596M

Growth

212%

Nerdio

Nerdio is the category-leading Microsoft EUC management platform with $100M+ ARR, 85%+ growth, profitable operations, and unicorn status, but is subject to existential single-vendor risk from Microsoft and financial opacity that limits investment-grade due diligence.

Valuation

$1B

ARR

$100M

Growth

85%

Mercor

Mercor is a real frontier-AI workflow franchise with credible benchmark and software upside, but the $10B mark already prices in cleaner economics, better diversification, and stronger trust than the public evidence currently proves, so the right call is TRACK.

Valuation

$10B

Revenue run-rate

$450M

Loft Orbital

Loft Orbital has credible platform, constellation, and sovereign traction, but limited financial disclosure and execution dependencies keep the stock of evidence at track, not buy, around an approximately $1 billion valuation.

Valuation

$1B

Writer

Writer has credible enterprise AI traction and differentiated full-stack product depth, but the $1.9B valuation already prices in sustained hyper-growth despite limited financial disclosure.

Valuation

$1.9B

Revenue run-rate

$47M

ARR

$47M

Growth

194%

CMR Surgical

CMR Surgical is a compelling strategic asset — the only globally deployed non-ISRG soft-tissue surgical robot with both CE mark and FDA authorization — but a 2021 vintage $3B valuation, fully opaque financials, and unproven US commercial execution justify a Track recommendation at medium confidence with high risk.

Valuation

$3B

AG1

AG1's genuine $600M revenue scale and durable subscription moat are real but insufficient to justify a conviction BUY absent audited financials, resolved FDA inquiry, and NRR disclosure; TRACK with medium confidence and high risk.

Valuation

$1.2B

Revenue run-rate

$600M

Vention

Vention shows credible platform momentum, strong named customer proof, and a potentially valuable physical-AI position, but public evidence still supports only a track stance until financial disclosure and cap-table opacity are resolved.

Revenue run-rate

$73M

Nexamp

Nexamp looks like a scaled and financeable community-solar platform, but current public disclosure is too thin to underwrite the equity confidently.

Deepwatch

Deepwatch has credible AI-native MDR product-market fit and enterprise customer proof, but pervasive financial opacity, three CEOs in under two years, and workforce reductions that targeted core MDR delivery staff make this a high-risk tracking position rather than an actionable buy until financial and leadership clarity improves.

Devo Technology

Devo has genuine cloud-native SIEM differentiation and strong NRR, but the $2 billion valuation at ~28x ARR is materially unsupported by current market comps — a constructive investment stance requires price discovery, an updated ARR milestone, or Gartner MQ re-inclusion before the risk-reward is favorable.

Valuation

$2B

Revenue run-rate

$70.6M

ARR

$70.6M

Growth

90%

NRR

120%

Lyten

Lyten holds genuinely differentiated Li-S battery chemistry and the acquired manufacturing infrastructure to scale it — but deep commercial opacity, no audited revenue, a stretched $1.3–1.5B estimated valuation relative to peers, and a heavy capital burden from two European facility acquisitions make this a Track at Low confidence until EXIM conversion, binding OEM contracts, or audited financial disclosure reduces uncertainty.

Valuation

$1.4B

Rappi

Track Rappi until its IPO S-1 surfaces audited financials; the equity-round valuation ($5.36 B) is stretched at ~4× unverified revenue while secondary markets clear at $1.77–2.0 B, a 66% discount.

Valuation

$1.9B

PathAI

Track PathAI through Roche deal close: the strategic price looks reasonable, but standalone economics remain too opaque for a stronger call.

SafetyCulture

SafetyCulture is a credible frontline-operations category leader with real scale, but the AU$2.5B headline price implies a 15-21x ARR multiple that outruns peers and the disclosure package.

Valuation

$1.7B

Chainalysis

Chainalysis remains the category leader in blockchain intelligence with durable government traction, but the valuation reset and opaque private financials keep the call at research-more and the ~$2.5B mark only marginally defensible.

Valuation

$2.5B

Revenue run-rate

$250M

ARR

$250M

Relativity Space

Relativity has a differentiated manufacturing-plus-launch thesis and meaningful signed demand, but Terran R is still pre-flight, backlog is not revenue, and opaque post-2021 financing plus brutal launch competition make the equity interesting to track rather than underwrite aggressively today.

OPay

OPay is a scaled and strategically important Nigerian payments leader, but limited audited disclosure, Nigeria concentration, and recurring compliance or fraud-control issues keep the case in track territory and make the reported IPO ambition look stretched.

Valuation

$3.1B

Vast Space

Vast Space has achieved real hardware progress with a credible team, first-mover positioning in post-ISS LEO stations, and a $500M institutional round—but the binary dependencies on SpaceX, NASA CLD award, and pre-revenue status at >$2B implied valuation make this a research-more / track situation, not a buy.

Valuation

$2.3B

MUBI

MUBI has a real premium arthouse brand, a rebound to 1.7M subscribers, and a differentiated streamer-curator-distributor model, but backlash sensitivity, hit-driven film economics, opaque segment margins, and a $1B mark justify a research-more stance.

Valuation

$1B

Revenue run-rate

$200M

Heven AeroTech

Heven AeroTech has credible strategic momentum in hydrogen UAS through Blue UAS Select, an Army BOA, and a fresh $100 million Series B, but the public record still lacks the revenue, backlog, and reliability proof needed to comfortably underwrite the current $1 billion financing anchor.

Valuation

$1B

OLIPOP

OLIPOP: Category-leading prebiotic soda brand with profitable growth, but litigation and exit risk cap near-term upside

Valuation

$1.9B

Revenue run-rate

$400M

Growth

100%

Chai Discovery

Chai Discovery is a technically credible AI antibody platform with blue-chip backers and a landmark Lilly partnership, but its $1.3B valuation is entirely premised on unvalidated preprint benchmarks, a single disclosed revenue partner, and zero public financial data—warranting deeper diligence before any commitment.

Valuation

$1.3B

Caris Life Sciences, Inc.

Caris is a scaled precision-oncology platform with credible growth, improving profitability, and ample liquidity, but the stock looks closer to fair value than bargain territory while DOJ, reimbursement, and controls risks remain open.

Valuation

$4.5B

Revenue run-rate

$864.8M

Growth

79%

Aikido Security

Aikido Security is a credible developer-first security platform with strong growth and product breadth, but the $1B valuation is ahead of what retained public operating evidence can support.

Valuation

$1B

Growth

400%

Underdog Fantasy

Underdog is a scaled consumer sports-gaming asset with real customer and revenue traction, but public evidence only supports a track recommendation because legal exposure and private-company disclosure gaps leave the current Series C valuation merely fair rather than clearly attractive.

Valuation

$1.2B

Radiant Nuclear

Radiant Nuclear has become one of the most credible private microreactor developers on public milestone evidence, but the current >$1.8B valuation signal still looks premature relative to zero disclosed revenue, stacked fuel and licensing gates, and concentrated customer proof.

Valuation

$1.8B

Imprint

Imprint appears strategically credible and commercially real, but incomplete disclosure, credit-and-funding intensity, and a stretched public valuation bridge support a research-more recommendation rather than a buy call.

Valuation

$1.2B

Growth

367%

BuildOps

BuildOps is a high-growth commercial FSM unicorn with a defensible vertical niche, but the $1B valuation — ~10× estimated ARR with no disclosed NRR or gross margin — demands exceptional execution and demands caution at entry.

Valuation

$1B

ARR

$97.4M

Growth

87.7%

Tailscale

Tailscale looks like a strong, technically differentiated secure-networking company with real customer love and credible category expansion, but the April 2025 Series C valuation remains hard to underwrite cleanly without public ARR, margin, and retention disclosure.

Valuation

$1.5B

Articulate Global

Articulate is a scaled, high-quality corporate learning platform, but the stale $3.75B 2021 mark and major disclosure gaps keep the investment case in research-more territory rather than buy territory.

Valuation

$3.8B

Revenue run-rate

$111.7M

ARR

$111.7M

Growth

32.7%

Tulip Interfaces

Tulip is a credible industrial SaaS platform at the Series D stage with strong product differentiation and a strategic Mitsubishi Electric alliance, but revenue opacity and valuation premium at USD 1.3B require deeper financial diligence before conviction.

Valuation

$1.3B

Truveta

Truveta has a differentiated provider-governed health-data moat and meaningful genomics optionality, but current valuation already discounts much of the upside given opaque economics and material privacy and execution risk.

Valuation

$1B

The Bot Company

The Bot Company combines an elite founding team, exceptional capital formation, and a genuine product opportunity in household robotics, but the complete absence of product proof, revenue, or customer validation — combined with a $2B confirmed valuation, Cruise founder liability, and deep sim-to-real technical risk — justifies a TRACK stance at high risk with low confidence.

Valuation

$2B

Eon

Eon's repeat-exit founders, tier-1 investor syndicate, and triple-digit revenue growth are compelling, but its $4B valuation is structurally unverifiable without disclosed ARR — TRACK until a data-room package closes the gap.

Valuation

$4B

CRED

CRED has built real premium consumer-fintech scale and improved operating leverage, but under-disclosed credit economics, partner complexity, and a still-stretched $3.5 billion mark make fresh underwriting premature.

Valuation

$3.5B

Growth

16%

Suno

Suno has built an unusually large, fast-monetizing AI music business, but unresolved copyright exposure and opaque unit economics keep the verified $2.45 billion mark in track-only territory.

Valuation

$2.5B

ARR

$300M

Fourier Intelligence

Fourier is a credible rehabilitation-robotics company with real installed-base proof and a technically serious humanoid program, but absent economics, customer-quality disclosure, and named paid humanoid deployments leave the current RMB 8 billion anchor hard to underwrite. Keep the company in research-more mode rather than commit capital at the public mark.

Valuation

$1.1B

Rapyd

Rapyd is strategically credible after PayU and clearly has real global payments scale, but opaque standalone disclosure, multi-entity execution risk, and only fair value at the 2025 mark support a TRACK recommendation rather than a buy.

Valuation

$4.5B

xAI

xAI has real compute, distribution, and execution advantages at scale, but the $230B valuation cannot be underwritten from public data — research-more until private financials are accessible.

Valuation

$230B

Shiprocket

Shiprocket combines real platform scale, improving unit economics, and strong cohort stickiness, but litigation overhang, courier concentration, and a stretched $1.21B private mark justify a TRACK stance until IPO pricing is visible.

Valuation

$1.2B

Growth

24%

NRR

103.51%

Element Biosciences

Element has become a credible sequencing challenger with real commercial momentum, but at or above the last disclosed unicorn mark the public evidence still supports research-more rather than an immediate buy.

Valuation

$1B

Growth

40%

Upwind Security

Upwind looks strategically relevant and commercially real, but the current $1.5 billion valuation is ahead of what the public record can actually underwrite. Recommendation: research-more until private diligence closes ARR, retention, margin, and cap-table gaps.

Valuation

$1.5B

Growth

900%

Eruditus

Eruditus has the strongest university-partner moat in online executive education and improving fundamentals, but its $3.2B flat-round valuation at 7.1x FY24 revenue — a 3-5x premium to public edtech comps — combined with opaque consolidated financials and undisclosed debt terms make research-more the only defensible call.

Valuation

$3.2B

Growth

12%

Socure

Socure looks like a real, scaled identity-and-risk platform with unusually strong private-company growth evidence, but unresolved valuation, disclosure, and control-system questions keep the investment posture at track rather than buy.

Valuation

$4.5B

ARR

$340M

Growth

54%

NRR

134%

Epic Games

Epic Games owns exceptional gaming and engine assets, but current public evidence supports only a cautious research-more stance because Fortnite concentration, platform dependence, and private-company opacity make the last hard $31.5 billion valuation look expensive.

Valuation

$31.5B

Rebellions

Rebellions has the strongest strategic positioning of any Korean AI chip startup, but the current $2.34B price is supported far more by sovereign-AI optionality and investor backing than by publicly disclosed commercial scale.

Valuation

$2.3B

Mura Technology

Mura Technology is the first commercial operator of hydrothermal advanced plastic recycling, with best-in-class environmental credentials and KBR's institutional backing, but faces critical financial opacity, an outstanding IP security charge, and the Böhlen cancellation as adverse commercial signals.

Heartflow

Heartflow is a real, scaled public coronary-AI platform with strong growth, high gross margins, and meaningful installed-base proof, but at roughly 9x forward EV/revenue the shares already discount much of that quality before plaque economics, retention, and concentration are publicly visible.

Valuation

$2.3B

Growth

41%

OPSWAT

OPSWAT appears to be a real, scaled OT/IT cybersecurity platform with credible product breadth and customer traction, but public evidence is too thin to underwrite the rumored ~$1.8B valuation or form a high-confidence investment view without audited financials and cap-table disclosure.

Keenon Robotics

KEENON is the uncontested global leader in commercial service robotics with 70,000+ deployed robots and IDC Triple No.1 rankings, but a four-year funding silence, complete financial opacity, and compounding geopolitical risk constrain conviction to a track/research-more stance at the implied $2B valuation.

Valuation

$2B